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Preface 
"Panic. 
Started too enthusiastic for a long run into the cold I stop, but it is too late. A wheezing 
sound swells from my chest and accompanies the cough symphony. All my efforts to take 
a deep breath are in vain. !feel like choking. More than ever, I'm conscious of one oft he 
vital functions of the human body known as respiration". 
The unique character of respiration is that it is not only regulated by automatic centers 
located in the brainstem, but also by voluntary signals originating from the cortex. As a 
consequence of this, we are also aware of the occurrence of a discrepancy between supply 
and demand with respect to ventilatory function, a discrepancy very familiar to subjects 
with asthma under the term shortness of breath. I have the disputable honor to be among 
these subjects, that is to say when it comes to asthmatic symptoms experienced in early 
childhood. Fortunately, symptoms completely disappeared in early adulthood and, to the 
present day, never returned. 
Have I grown out of asthma? Or are there merely no symptoms at the moment? And, if 
the latter is true, do I carry the risk of a relapse later in life and, moreover, should I take 
anti-inflammatory medication? 
That is what this thesis is about 
Chapter 
General introduction 
1.1 Definition of asthma 
Asthma has been well recognized since ancient times. Although there may be reference to 
asthma in Egyptian papyrus records from the second millennium BC, it was differentiated 
as a discrete disorder of breathing by the Greeks. 
Figure 1: Hippocrates 
The description of asthma as a disease with airflow limitation as the main component 
resulted in a definition derived from the first CIBA symposium in 1959: 
"Asthma is a condition with widespread narrowing of the bronchial airways, which 
changes in severity over short periods ~f time, either spontaneously or under treatment, 
and is not due to cardiovascular disease" 
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This definition of asthma has been updated as aspects of its pathophysiology became 
recognized. In 1987, for example, the American Thoracic Society emphasized bronchial 
hyperresponsiveness in the definition of asthma ( 1 ). However, the growing evidence for 
the central role of inflammation in the pathogenesis of asthma led the 1991 National 
Asthma Education Program (Expert) Panel (NAEPP) Report from the National Institutes 
of Health (NIH) to define asthma as a lung disease with the following characteristics: 
Variable airflow obstruction. 
2 Airway inflammation. 
3 Increased airway responsiveness to a variety of stimuli. 
The concept of airway inflammation as central element in asthma was incorporated in a 
1995 workshop report, which was revised in 2002, from the Global Initiative for Asthma 
(GINA), sponsored by the World Health Organization (WHO) and the NIH, where 
asthma was finally defined as: 
" ... a chronic inflammatory disorder of the airnays in which many cells and cellular 
elements play a role. The chronic inflammation causes an associated increase in ainvay 
hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest 
tightness, and coughing, particularly at night or in the early morning. These episodes are 
usually associated with widespread but variable aiiflow limitation that is often 
reversible, either spontaneously or with treatment. " In 1997, the NAEPP expert panel 
report II guidelines subsequently included the variable presence of airway remodelling 
aspects in the working definition of asthma. 
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Presumably, because of the heterogeneity of the syndrome there will never be an all 
embracing definition of asthma, creating difficulty both in obtaining accurate numbers to 
determine the prevalence of asthma and in comparing the results of different studies. 
11 
Chapter 1 General introduction 
1.2 Classification of asthma 
"Physicians think they do a lot for a patient when they give his disease a name" 
Immanuel Kant 
Clinically usable classifications of disease are dependent on good descriptions of tissue 
morphology characteristics. So far, because of concerns with reference to the safety and 
ethics of employing invasive methods such as flexible bronchoscopy to obtain bronchial 
biopsies, the use of histopathology to define and classifY asthma has lagged behind. 
Atopic and non-atopic forms of asthma 
Asthma may be subdivided according to the presence or absence of atopy. Atopy is 
defined as the enhanced sensitivity of individuals to common and otherwise innocuous 
aeroallergens such as house dust mites, pollen and allergenic substances of animal origin. 
Figure 2: A source of allergens 
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Classification of asthma according to severity 
The GINA workshop has proposed the first classification of asthma based on clinical 
features as well as treatment requirements. This classification makes use of asthmatic 
symptoms, spirometry values, peakflow variability and the necessity of using short acting 
~2-agonists. Asthma is categorized as either intermittent or persistent. Persistent asthma is 
further subdivided into mild, moderate and severe. Although there is much overlap 
among these groups- and some patients do not fit easily into one category- this 
classification provides a useful guide for physicians in assessing their patients' asthma 
severity and prescribing the correct treatment. 
13 
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Classification of asthma 
II 
m 
IV 
Clinical features 
Intermittend 
Intermittent symptoms< once a week. 
Brief exacerbations. 
Nocturnal symptoms< twice/month. 
Normal lung function between episodes. 
Mild persistend 
Symptoms> once a week, but< once a day. 
Nocturnal symptoms> twice a month, but< 
once a week. 
Normal lung function between episodes. 
Moderate persistend 
Symptoms daily. 
Exacerbations affect activity and sleep. 
Nocturnal symptoms at least once a week. 
FEV 1 60- 80% predicted or 
PEF 60-80% of personal best 
Severe persistent 
Symptoms daily. 
Frequent exacerbations. 
Frequent nocturnal asthma symptoms. 
FEV1 < 60% predicted or 
PEF < 60% of personal best 
General introduction 
Medication required 
None necessary 
Inhaled glucocorticosteroid 
(:5 500 )..lg BDP or equivalent) 
Consider theophy!line, cromone, or 
Jeukotriene modifier. 
Inhaled g\ucocorticosteroid 
(200 ~ 1000 )..lg BDP or equivalent) 
plus long~acting.inhaled Pragonist. 
Consider theophylline, leukotriene 
modifier, long-acting oral P2-agonist or 
higher dose inhaled glucocorticosteroid. 
Inhaled glucocorticosteroid 
( > 1000 !J.g BDP or equivalent) 
plus long-acting.inhaled Pragonist 
plus theophylline, leukotriene modifier, 
long-acting oral Pragonist or oral 
glucocorticosteroid. 
Based on US DHSS, NIH, NHLBI, Asthma Management and Prevention. Global Initiative for Asthma. A 
practical guide for public health officials and health care professionals. NIH publication no. 96-3659A, 
December 1995, revised in 2002. 
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1.3 Epidemiological aspects 
Prevalence 
The literature is replete with studies reporting the prevalence of asthma from different 
countries around the world. However, comparison of these prevalence estimates, ranging 
from 1% to 30%, has been difficult given the different methods used between studies. 
One multicenter study, the International Study of Asthma and Allergy in Children 
(ISAAC) has addressed this issue, and confirmed the wide variations in prevalence of 
asthma symptoms, even though assessed with the same instruments, in children 
worldwide (figure). There is substantial evidence that asthma prevalence is increasing 
throughout the world (2). 
N America 
Latin America 
WEurope 
N+E 
0 5 10 
Figure 3: Prevalence(%) of asthma worldwide.50 
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The rate of increase in prevalence is such that it can only be rooted in environmental 
changes and not in genetic factors, although it is assumed that the latter are important for 
individual susceptibility to develop asthma (3). Next to the increase in asthma prevalence, 
there has been a similar rise in asthma severity, as suggested from hospital admission 
records (4). 
Despite the improvement in asthma management, of which the emphasis on 
antiinflammatory treatment may have played a major role in the gradual decline in 
mortality (5), the reduction in deaths has been small and disappointing (6). There are 
probably various reasons for the failure to further decrease mortality due to asthma, 
including socioeconomic factors, lack of appreciation of disease severity by both patients 
and doctors resulting in non-compliance, and an overall increase in patients with asthma. 
Natural history of asthma 
Our understanding of the natural history of asthma has improved through the more 
specified definitions of asthma phenotypes that resulted from large longitudinal cohort 
studies. Risk factors for the development of childhood asthma including atopic status (7), 
genetic and familial factors (8), respiratory infections (9), and outdoor and indoor 
pollution are now more clearly appreciated. New information on the relation of viral 
wheezing episodes in infancy to later asthma-like syndromes is evolving (10, 11). Data 
from these studies suggest that recurrent obstructive symptoms remit in a large number of 
children who develop these symptoms during the first 3 years of life, and low lung 
function seems to be the main risk factor for these transient episodes. On the other hand, 
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children who will go on to develop persistent wheezing beyond infancy and early 
childhood usually have a family history of asthma and allergies and present with allergic 
symptoms very early in life (12, 1 3). Fmihermore, epidemiological studies have shown 
that between 30 and 70 percent of those children with (early onset) atopic asthma 
markedly improve or become asymptomatic by early adulthood (13, 14). However, a 
considerable proportion of asthmatics in "clinical remission" will have a relapse later in 
life (14, 15), making the eventual "remission" rate in the middle aged and elderly small 
and presumably dependent on initial degree of bronchial hyperresponsiveness (BHR), 
Forced Expiratory Volume in one second (FEV 1), and smoking behaviour (16-18). 
Besides, if asthma persists into adulthood, the likelihood of remission seems to be even 
lower ( 18). It is intriguing whether early use of steroids or other newer modalities of 
therapy can alter the natural history of asthma. 
17 
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Figure 4: Natural history of atopic asthma 
Effect of asthma on lungfimcdon 
Persistent 
remission 
25% 
Little is known about the effects of asthma on lung function, particularly early in life. In 
studies concerning pulmonary function of asthmatic children in later adulthood, 
persistently lower lung function values were found in subjects with more severe asthma 
in childhood (19-21). Even so, the duration of asthma seems to correlate with the degree 
of impairment in lung function. Baseline data from 1041 children with mild to moderate 
asthma in the Childhood Asthma Management Program (CAMP) study found a 
significant correlation between asthma duration and lower lung function, greater 
bronchial hyperresponsiveness, more asthma symptoms, and greater use of medication. A 
rapid decline in lung function of asthmatics as compared with healthy controls was 
18 
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confirmed in another study, where the decline in FEV1 among subjects with asthma was 
38 ml per year, compared with 22 ml per year in those without asthma (22). 
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1.4 Pathogenesis of asthma 
Histology 
The airways are lined with mucosa consisting of epithelium, basement 
membrane/reticular basement membrane (RBM), and lamina propria. The subepithelium 
is a cell-rich area 100 11m deep in the lamina propria. A spirally oriented smooth muscle 
layer surrounds the bronchial mucosa. 
Figure 6: Bronchial mucosa 
Mucosal inflammation 
"Inflammation is not itself considered to be a disease but a salutary operation .. but when 
it cannot accomplish that salutary purpose. it does mischief" 
John Hunter 
20 
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Although the inflammatory basis of astluna is well established, the mechanisms involved 
remain incompletely understood (23). Airway inflammation involves a complex network 
of interactions between inflammatory and structural cells and their mediators. Fibreoptic 
bronchoscopy has greatly improved our understanding of the pathogenesis of asthma 
(24). It is, however, important to appreciate in this regard that astluna is a syndrome of 
signs, symptoms, and laboratory abnormalities that is probably composed of many 
diseases, each with its own genetic and biochemical characteristics. The common 
denominator and primary physiologic abnormality in asthma is airway obstruction, which 
is most likely due to cellular inflammation and subsequent cytokine production, oedema, 
and smooth muscle infiltration with mast cells. 
a 
Figure 7: Flexible bronchoscopy (a) and example of an inside view (b). 
Published with permission of Dr SE Overbeek 
b 
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Inflammation is an early event in asthma, and infiltrating cells are uniformly present in 
airway biopsies obtained from newly diagnosed patients (25). Abundant evidence 
suggests that allergen-reactive type 2 T helper (Th2) cells, with eosinophils and mast 
cells as most important effector cells, orchestrate asthmatic airway inflammation (26, 27). 
The level of eosinophilia in the airway wall is, hereby, apparently the most distinguishing 
feature of bronchial asthma that seems to be correlated with asthma severity (28). Along 
with interleukin (IL)-5, a Th2 cytokine, and eotaxin, a chemoattractant for eosinophils, 
eosinophil-derived products such as major basic protein (MBP) have been put forward as 
markers ofeosinophjl participation in the pathogenesis of asthma (29). Also, elevated 
numbers of mast cells have been found in the bronchial mucosa of atopic and non-atopic 
asthmatic subjects (30, 3 1 ). Release of mediators from mast cells, such as granule-
associated tryptase and chymase, leads to immediate bronchoconstriction and enhances 
airway inflammation (3 1 ). 
How numbers and activity levels of the different cell types and mediators in the bronchial 
mucosa relate to less in vasive markers of airway inflammation, is, up ti ll now, still matter 
of debate (32-34). 
Figur e 8: Bronchial mucosa showing 
extensive deposition of eosinophil derived 
major basic protein (red) beneath the 
ret icular basement membrane. 
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Airway remodeling 
In conjunction with, or because of, the inflammatory process structural changes occur 
that are known as airway remodeling (23). These structural changes of the airway walls 
occur early in the course of the disease (35, 36). As a result of airway remodeling, 
alterations in the airway epithelium, reticular basement membrane, subepithelium and 
submucosa develop, leading to thickening of the smooth muscle layer and airway walL 
Moreover, these morphological changes may not be completely reversible (3 7). Attempts 
to delineate the physiologic consequences of such specific structural aberrations are at an 
early stage. Probably, (irreversible) airway narrowing and bronchial hyperresponsiveness 
may result from these changes in the mucosa and submucosa (38-42). The exact 
physiological consequences of airway wall thickening are, however, still incompletely 
understood and require more detailed investigation (23, 43). This was also part of the 
guidelines of the 1997 NAEPP expert panel report II, which stated that "the importance 
of airway remodeling and the development of persistent airflow limitation need further 
exploration and may have significant implications for the treatment of asthma". 
Remodeling of the airulay mucosa and submucosa can be assessed by measurement of the 
reticular basement membrane (RBM) thickness ( 44) and extent of epithelial shedding 
(45). Also, collagen deposition (46) and microvascular proliferation (47) are quantifiable 
aspects of airway remodeling. 
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Figure 9: RBM Figure 10: Epithelial desquamation 
Epithelial shedding 
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1.5 Establishing the diagnosis 
Traditionally, the presence of asthma is suggested by a compatible history of cough, 
sputum, wheezing, chest tightness or breathlessness, particularly when the symptoms are 
variable. Physical examination is of little value in recognizing asthmatics. Conversely, 
pulmonary function measurements and measurement of the bronchial response to inhaled 
stimuli can help in identifying asthmatic subjects. Up till now, diagnosis and treatment 
decisions are mostly based on assessments of symptoms and simple measures of lung 
function. Only recently it has been put fonvard to include aspects of airway inflammation 
in the decision-making around diagnosis and therapy. 
Lungfimction 
Measurement of lung function, particularly the reversibility of bronchoconstriction, 
provides an easy to obtain direct assessment of airflow limitation. According to GINA 
guidelines, at least a 12 percent improvement in FEY 1, either spontaneously, or after 
inhalation of a bronchodilatator, or in response to a trial of anti-inflammatory therapy 
favors a diagnosis of asthma. 
Bronchial hyperresponsiveness 
Bronchial hyperresponsiveness (BHR) is one of the hallmarks of asthma and is often used 
as an indicator of asthma severity. Several studies have shown a clear relationship 
25 
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between BHR and airway inflammation in symptomatic asthma (33, 48, 49), although 
there are clues that the relationship is not simple (32, 50). The degree of airway 
responsiveness can be assessed with a variety of inhaled stimuli, such as methacholine 
(MCh) or adenosine-Y-rnonophosphate (AMP). MCh induces airway constriction via 
direct stimulation of the muscarin receptors on airway smooth muscle cells. AMP, on the 
other hand, causes airway narrowing mainly through indirect mechanisms, in particular 
stimulation of mast cells and activation of neuronal reflexes in the lung (48). Since the 
presence of mast cells in the mucosa and airway smooth muscle cells is believed to play a 
predominant role in atopic asthma, the bronchial response to AMP, in addition to the 
response to MCh, may serve as indicator of the acute inflammatory process. 
Figure 11: Lung function equipment with different doses of methacholine shown on the left 
Nitric oxide 
Nitric oxide synthase (NOS) is a newly identified enzyme system active in airway 
epithelial- and endothelial cells, macrophages, neutrophils, mast cells, autonomic 
26 
Chapter 1 General introduction 
neurons, smooth muscle cells and fibroblasts. Nowadays, nitric oxide (NO) is known as a 
mediator of vasodilatation and bronchodilatation. The presence of an inducible form of 
NOS (iN OS) in human lungs suggests that increased production of NO, probably brought 
about by cytokines, may be relevant to the pathology of asthma (5!). Many studies 
concerning atopic asthma demonstrate enhanced NO levels in exhaled air (52, 53). 
Furthermore, exhaled NO (eNO) levels are lowered by anti-inflammatory therapy, which 
offers opportunities to monitor compliance with- and effectiveness of treatment (54). The 
measurement ofeNO can be performed repeatedly, even in children and patients with 
severe airflow obstruction, in whom invasive techniques are not feasible or desirable. 
Studies regarding eNO report a weak relationship between eNO levels and BHR (55, 56), 
indicating the complex interrelationships between the mechanisms involved. An 
increasing number of papers shows evidence that eNO is related to atopic asthma more 
than to non-atopic asthma or atopy per se. It was recently demonstrated that atopic 
asthmatic children had higher geometric mean eNO levels than non-atopic asthmatic 
children, atopic non-asthmatic children, or non-atopic non-asthmatic children, suggesting 
that both atopy and asthma are important in the context of elevated eNO levels (57). The 
usefulness and specificity of eNO values with respect to the monitoring of airvvay 
inflammation in atopic asthma are also still under investigation (58-62). It is proposed 
that airway acidification leads to non-enzymatic NO formation independent of 
inflammation, which may occur during acute severe asthma (63). Nevertheless, it is 
attractive to speculate that this simple, non-invasive test could be used to monitor the 
inflammatory status of the asthmatic airway during treatment with anti-inflammatory 
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medication (64-67). Additionally, exhaled NO may be useful as a diagnostic tool in 
asthma. 
The measurement of exhaled NO has been subject to alteration. In 1997, the European 
Respiratory Society Task Force (68) published recommendations concerning the 
measurement of NO in exhaled air. Briefly, eNO can be measured with a 
chemiluminescence analyzer with a detection range of< 0.1 - 500,000 ppb. The 
measurement circuit consists of a mouthpiece connected to a two-way non-rebreathing 
valve through which subjects inhale ambient air or NO-free medical air, depending on the 
ambient air NO concentration. Subjects inhale to TLC and immediately exhale for as long 
as possible into a tube, with an in-line flow resistor to prevent contamination of exhaled 
air with air from the upper airways, which have a high NO content (69). Exhalation is 
performed at low flow, providing NO to diffuse properly from the lining epithelium to 
the bronchial lumen when air passes through the conducting airways, thereby amplifying 
the signal (70-72) A fine tube samples exhaled air from a side port situated directly after 
the mouthpiece to conduct the air to the analyzer continuously. 
Figure 12: The author experiences 
an exhaled NO measurement 
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Hydrogen peroxide in exhaled air 
Exhaled air condensate provides a noninvasive means of obtaining samples from the 
lower respiratory tract. Leukocytes involved in the asthma inflammatory cascade 
(predominantly eosinophils, mast cells and neutrophils) release mediators, including 
reactive oxygen species, i.e. superoxide anion that is dismutated to hydrogen peroxide 
(H20 2). Hz02 in exhaled air has therefore been proposed as a marker of airway 
inflammation (52, 73-75). 
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Induced sputum 
Investigation of inflammatory mediators and cells in sputum induced by inhalation of 
nebulized hypertonic saline is increasingly used to monitor airway inflammation in 
asthma, and can be performed safely in subjects with moderate to severe asthma when 
carried out under carefully monitored conditions (52, 62, 76). It is suggested that analysis 
of induced sputum reveals infonnation qualitatively similar to that obtained by analysis 
of bronchoalveolar lavage fluid or bronchial biopsy specimens (77). Sputum induction is 
appreciated not only for being noninvasive and repeatable (78) but also for yielding 
samples more concentrated and richer in airway secretions than those obtained by 
bronchoscopy (79). 
Blood eosinophils 
It has been proposed that determination of numbers of eosinophils in peripheral blood 
may also help to indicate the level of ainvay inflammation, thereby providing a surrogate, 
less invasive marker to monitor asthma. Indeed, within a population of atopic asthmatics, 
ainvay wall eosinophilia weakly correlates with eosinophilia in peripheral blood (34 ). 
Flexible bronchoscopy 
From all indices of ainvay inflammation, bronchial mucosal biopsy investigations still 
provide the golden standard (80, 81). How numbers and activation state of the different 
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cell types and mediators in the bronchial mucosa relate to less invasive markers of airway 
inflammation, including bronchial hypenesponsiveness, circulating eosinophils and eNO, 
is largely unclear (32-34). 
,... 
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Figure 13: Bronchoscopy as a research tool for the study of asthma pathogenesis. A fo rceps taki ng a 
biopsy from a subcarina of one of the main bronchi is shown on the right. 
a b 
Figure 14: Normal (a) and inflamed (b) airways, with swelling of the mucosa, excessive mucus production 
and easy bleeding in the latter. 
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Analysis of bronchial biopsy specimens 
Immunostained sections of bronchial biopsies can be analyzed with computer-assisted 
image analysis, a method which provides highly reproducible and reliable parameters of 
asthmatic airway inflammation (82). After setting of the reticular basement membrane 
and epithelial margins interactively, the program is primed to analyze the epithelium as 
well as an area I 00 !!m below the reticular basement membrane. Artefacts are excluded 
from analysis. The ratio of positive stained area divided by the total area analyzed is 
taken as measure for each immunohistochemical staining. 
Figure 15: Image analysis 
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c 
Figure 16: Interactively setting of the reticular basement membrane (black, b), 100 ~-tm subepithelial zone 
(green area, c), and epithelial lining (red, d) in image analysis. 
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1.6 Treatment of asthma 
Asthma is a chronic inflammatory disease of the airways involving a characteristic 
picture of airway infiltration with lymphocytes, eosinophils, and mast cells, subepithelial 
deposition of collagen, and hypertrophy and/or hyperplasia of smooth muscle cells, 
goblet cells and submucosal glands. The consequences of this chronic inflammatory 
process are still not understood in detail but include variable or persistent symptoms, 
bronchial hyperresponsiveness, and attacks of airflow limitation that may require 
emergency care or hospitalization and can even lead to death. Pathology studies have 
shown that antiinflammatory therapy can reverse or suppress airway inflammation (35, 
83-85), whereas prospective controlled clinical trials have demonstrated that it can also 
diminish symptoms, reduce bronchial hyperreactivity, and reduce the frequency and 
severity of exacerbations (86-88) as well as the rate of decline in lung function (37). It is 
also highly likely, although it is not yet proven, that inhaled antiinflammatory therapy 
reduces the risk of asthma fatality and prevents, retards or even reduces airway wall 
remodeling (47, 89-92). These beneficial effects are easily shown in patients with 
moderate to severe asthma. Although benefits are also applicable to patients with mild 
asthma, it is less certain that the cost and harm of continuous antiinflammatory therapy 
are justified for the mildest forms of the disease (65, 85, 93, 94). For these patients, the 
most important issue that remains to be resolved is which factors lead to permanent 
airflow obstruction and what the effects of early, sustained treatment are on the 
possibility to reach complete sustained remission of asthma (89). 
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Inhaled corticosteroids have now become established as antiinflammatory therapy of 
choice in patients with persistent asthma (5). Inhaled corticosteroids largely avoid the 
adverse effects associated with oral steroids and are now also recommended in newly 
detected disease (94). Several different inhaled corticosteroids are available as 
therapeutic options for the treatment of asthma, including include fluticasone propionate, 
beclomethasone dipropionate, and budesonide. 
Other therapies 
Other drugs widely used to treat asthma include beta 2-agonists, theophylline, 
cromones, and anticholinergic agents. For acute asthma attacks, the inhaled beta 2-
agonists are the most effective bronchodilators (95). Short- acting forms, such as 
salbutamol and terbutaline, give rapid relief; long-acting agents, i.e. salmeterol and 
formoterol, provide sustained relief and reduce nocturnal and exercise-induced asthma 
(96). Although some authors postulate that an effect on airway inflammation and 
remodeling is lacking (97), others have shown that, in addition to their bronchodilator 
action, long-acting ~2-agonists may also bring about changes in airway inflammation 
and/or remodeling itself, including a decrease in mast cell mediator release (98) and in 
airway wall vascularity (47, 99). 
Adverse effects are of minor importance when these drugs are used properly (100). The 
anticholinergic bronchodilators are more useful for treating COPD than chronic asthma. 
These drugs have virtually no side effects, and their onset is slower and their action 
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longer than that of inhaled beta 2-agonists. Finally, the antileukotrienes seem to provide 
some bronchodilation and have a minor effect on eosinophilia, with minimal side effects. 
Combination therapy 
The dose-response curve to inhaled corticosteroids is relatively flat, and there is a strong 
scientific rationale for adding long-acting inhaled beta2-agonists, which may be 
equivalent or preferable to increasing the dose of inhaled corticosteroids in patients with 
moderate-to-severe asthma (88, 101, 102). 
Mild asthma 
The anticipated natural history of the disease may influence treatment considerations. If 
mild asthma is destined to remain mild into old age, treatment is best determined by the 
symptoms of asthma at that time. On the other hand, if the chronic eosinophilic 
inflammatory process progresses over time to subepithelial fibrosis and irreversible 
airflow limitation, the early initiation and prolonged continuation of antiinflammatory 
therapy might be beneficial. Unfortunately, the ability to predict the outcome of mild 
asthma is limited at present. As yet, no studies have been performed that provide long-
term physiologic and histologic follow-up over many years in a large cohort of 
individuals with mild asthma. At present, NAEPP guidelines indicate that patients with 
mild intermittent asthma are best treated with intermittent use of an inhaled beta-2-
36 
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selective adrenergic agonist, where antiinflammatory medications are only needed when 
asthmatic symptoms are reported more than twice a week (mild persistent asthma). 
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1. 7 Growing out of asthma 
Epidemiological work has shown that symptoms of atopic asthma often disappear in 
early adolescence (13). This apparent improvement eventually leads to cessation of 
treatment and discontinuation of routine check-ups at the out-patient clinic. The 
classification "clinical remission" is used to identify these subjects who are believed to 
have outgrown their asthma. Unfortunately, 30 to 80% of these subjects in clinical 
remission experiences a relapse of symptoms later in life (2). The factors responsible for 
this high relapse rate are unknown. Several authors have demonstrated spirometry 
abnormalities and/or bronchial hyperresponsiveness in subjects during clinical remission 
of asthma ( 103-1 05). It is unclear whether these functional aberrations reflect ongoing 
airway inflammation or merely indicate structural changes of the airways as a late 
consequence of childhood asthma. Defining asthma as chronic inflammatory disease, 
persistent airway inflammation during clinical remission of atopic asthma could possibly 
account for the high relapse rate (1 06). On the other hand, from several studies it has 
emerged that structural changes, known as airway remodelling, finally lead to thickening 
of the airway wall (39, 41). A relationship between airway wall thickening and impaired 
airflow has been made plausible (I 07, I 08). How the different aspects of airway wall 
thickening contribute to altered airway function is, however, incompletely understood 
(23, 43). If airway wall thickening is present in subjects during clinical remission of 
asthma, it could at least in part account for the functional abnormalities found during 
'remission', but even so for the high relapse rate. In particular ongoing airway 
inflammation arises the question whether anti-inflammatory therapy should be continued 
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in subjects with apparently outgrown asthma. Monitoring airway inflammation, 
preferably without the use of invasive techniques, will then be needed to show the effect 
of treatment. 
The discrepancy between the lack of symptoms and ongoing airway inflammation 
remains an other problem to be resolved. It is well-known that the correlation between 
symptom perception and other indices of asthmatic severity, such as the degree of airflow 
obstruction, is poor (1 09, 11 0). Poor perception of airway narrowing may, on its turn, 
itse1flead to undertreatment of asthma (111, 112). Thus, the concept ofb1unted 
perception of dyspnea in subjects with apparently outgrown asthma is likely of great 
clinical relevance. 
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Aim of the study 
"Everything hinges on the matter of evidence" 
Car! Sagan 
As stated in the introductory remarks, various questions arise from the epidemiological 
fact that a great deal of subjects with apparently outgrown asthma experiences a relapse 
of symptoms of asthma later in life. ln the present thesis, the next questions will be 
addressed: 
Are we able to produce convincing arguments of ongoing airway inflammation 
and/or remodeling in subjects who are believed to have outgrown their asthma? 
To address this question, we measured spirometry values, bronchial responsiveness to 
different inhaled stimuli, and exhaled nitric oxide levels in adolescents in clinical 
remission of atopic asthma. Clinical remission was defined as complete absence of 
symptoms without the use of any medication in the year preceding the study. Chapter 3 
describes the results of this study, wherein subjects in clinical remission were compared 
with subjects with symptomatic asthma and healthy controls. In Chapter 4 invasively 
obtained "proof' of ongoing airway inflammation and remodeling during clinical 
remission of atopic asthma is discussed. By means of flexible bronchoscopy, biopsies 
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were obtained from the airway walls in all subjects from the three study groups. A 
comparison of biopsy findings, including inflammatory cell type density and various 
indices of airway remodeling, was made between the groups. Also, data were compared 
with noninvasive markers of airway disease, such as exhaled nitric oxide levels and 
bronchial responsiveness to inhaled stimuli. 
2 If persistent airway inflammation can be demonstrated during clinical remission, 
could blunted symptom perception explain the discrepancy between the lack of 
symptoms and ongoing disease? 
This question will be dealt with in chapter 5, where a study is described in which we 
obtained "BORG" dyspnea scores from subjects in clinical remission and subjects with 
symptomatic asthma during MCh and AMP provocation. 
3 Would subjects with subclinical airway inflammation and remodelling benefit from 
antiinflammatory treatment in the short-term? 
In chapter 6, a double blind, longitudinal, placebo controlled study is described in which 
subjects in clinical remission of atopic asthma are treated for three months with either the 
salmeterol/flixotide propionate combination product (Seretide) or placebo. Again, 
invasive- as well as non-invasive indices were obtained from all subjects before and after 
treatment. 
4 Asthma remission- does it exist? 
This question will be dealt with in chapter 7. Whether "true" remission of asthma can be 
reached with or without the aid of prolonged anti-inflammatory treatment is as yet 
unknown. A review of relevant literature as well as a proposal to deal with subjects with 
apparently outgrown asthma is given. 
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ABSTRACT 
Symptoms of atopic asthma often decrease or even seem to disappear around 
puberty. The aim of this study was to investigate whether this so-called clinical 
remission is accompanied by remission of airway inflammation, since symptoms 
relapse in a substantial proportion of subjects later in life. 
To assess indicators of inflammation and/or structural damage of the ainvays, exhaled 
nitric oxide (eNO) and bronchial responsiveness to adenosine-5'-monophosphate (AMP) 
and methacholine (MCh) were determined in 21 subjects in clinical remission of atopic 
asthma. Clinical remission was defined as complete absence of symptoms of asthma 
without the use of any medication in the year preceding the study. Results were compared 
with those of 21 patients with current asthma and 18 healthy control subjects. We found 
significantly higher eNO values in the remission group than in healthy controls 
(geometric mean 18.9 ppb and 1.0 ppb, respectively; p < 0.001) whereas eNO values of 
the remission group and those of the subjects with current asthma (geometric mean 21.9 
ppb) were similar (p ~ 0.09). The responsiveness to both AMP and MCh of subjects in 
clinical remission was significantly higher as compared with responsiveness of healthy 
controls, and lower than responsiveness of subjects with current asthma. A significant 
correlation could be established between eNO and responsiveness to AMP, but not 
between eNO and responsiveness to MCh. The results of this study are suggestive of 
persistent airway inflammation during clinical remission of atopic asthma. We speculate 
that subclinical inflammation is a risk factor for asthma relapse later in life, and that eNO 
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and responsiveness to both AMP and MCh can be used as different, non-invasive indices 
of the inflammatory process of the airways. 
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INTRODUCTION 
Asthma is a chronic inflammatory disorder of the airways, characterized by cellular 
infiltration, cellular activity and cell damage, but also by oedema, vascular leakage, and 
hypertrophy/hyperplasia of resident cells, as there are goblet cells and smooth muscles. 
Structural changes of the airway walls occur early in the course of the disease (1, 2). 
Epidemiological studies have shown that symptoms of atopic asthma often begin in early 
childhood and improve or seem to disappear around puberty (3, 4). However, a 
considerable proportion of asthmatics in "clinical remission" will have a relapse later in 
life (4). Several studies have shown spirometric abnormalities and bronchial 
hyperresponsiveness (BHR) to methacholine (MCh) or cold air challenge during clinical 
remission of asthma (5, 6). It is unknown whether these functional abnormalities, which 
are supposed to be indicative of asthma severity with respect to symptomatic asthma, 
reflect persistent airway inflammation or merely indicate residual airway damage. These 
considerations seem to be important, as it is reasonable to believe that persistent airway 
inflammation during clinical remission of atopic asthma has substantial impact on the risk 
of relapse at a later age. The question arises whether other available non-invasive 
physiological techniques can give information about the presence of an ongoing 
inflammatory process. 
Nitric oxide synthase (NOS) is a newly identified enzyme system active in airway 
epithelial- and endothelial cells, macrophages, neutrophils, mast cells, autonomic 
neurons, smooth muscle cells, and fibroblasts. The existence of an inducible form of NOS 
(iN OS) in human lungs suggests that increased production of NO, probably induced by 
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cytokines, may be relevant to the pathology of asthma (7). Many studies concerning 
atopic asthma demonstrate elevated NO levels in exhaled air (8, 9). Furthermore, exhaled 
NO (eNO) levels are decreased by antiinflammatory therapy, which offers opportunities 
to monitor compliance with and effectiveness of treatment (10). The measurement of 
eNO can be performed repeatedly, even in children and patients with severe airflow 
obstruction, in whom invasive techniques are not feasible or desirable. Studies regarding 
eNO reported a weak relationship between eNO levels and BHR (II, 12), indicating the 
complexity of mechanisms involved in atopic asthma. The usefulness and specificity of 
eNO values with respect to the monitoring of airway inflammation in atopic asthma are 
still under investigation. 
BHR is one of the hallmarks of asthma and is often used as an indicator of asthma 
severity. Several studies have shown a significant correlation between BHR and airway 
inflammation in symptomatic asthma (13-15). The degree of airway responsiveness can 
be assessed with a variety of inhaled stimuli, such as MCh or adenosine-5'-
monophosphate (AMP). MCh induces airway constriction via direct stimulation of the 
muscarin receptors on airway smooth muscle cells. AMP, on the other hand, causes 
airway narrowing mainly through indirect mechanisms, in particular stimulation of mast 
cells and activation of neuronal reflexes in the lung (14). Since mast cells are believed to 
play a predominant role in atopic asthma, the bronchial response to AMP, in addition to 
the response to MCh, may serve as indicator of the inflammatory process. 
The aim of this study was to measure eNO values and bronchial responsiveness to 
MCh and AMP, each reflecting distinct parts of the inflammatory process in the airways, 
in previously well-documented atopic asthmatic adolescents who were in clinical 
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remission for more than one year. Data were compared with data on adolescents with 
current asthma and healthy control subjects. 
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METHODS 
Subjects 
Adolescents, 18 - 25 years of age, with atopic asthma were selected from the Sophia 
Children's Hospital discharged patients files. Clinical remission was assumed if subjects 
reported complete absence of cough, wheezing and breathlessness at rest and on exertion 
and had not taken any medication in order to control asthmatic symptoms for at least 12 
mo before to the study. Twenty-one eligible subjects in remission were included, and 
compared with 21 patients with asthma who had persistent symptoms at least once a 
month in the year preceding the study, and used inhaled B2-agonists on demand in order 
to relieve symptoms. All subjects had a history of wheezing and chest tightness and were 
previously diagnosed as having atopic asthma according to American Thoracic Society 
(ATS) criteria (16). In the past, all had a provocation dose/concentration ofMCh or 
histamine producing a 20 % fall in FEY 1 of S 150 ).lg (dosimeter method) or S 8 mg·mL~ 1 
(2-min tidal breathing method), and/or had an FEY1 reversibility 2 12% of predicted 
normal value. All had evidence of atopy defined by radio allergosorbent test (RAST) 
Class 2 or higher for at least one common airborne allergen. Participating subjects were 
lifelong nonsmokers, in stable clinical condition and did not take inhaled steroids, 
including nasal steroids, or anti-allergic medication such as cromoglycate and 
antihistamines for at least 1 yr before the study. 
Eighteen healthy nonsmoking young adult volunteers were recruited via advertisement 
and served as control subjects. They had a negative personal and first-degree family 
history of asthma and atopy. Common exclusion criteria were an inability to perform lung 
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function tests reproducibly, perennial rhinitis, and other illnesses that may affect lung 
function. None of the subjects in the study reported symptoms of respiratory infection in 
the month prior to the study. The study was approved by the Medical Ethics Committee 
of the Erasmus University and University Hospital Rotterdam. 
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Study Design 
We performed a cross-sectional study with three visits on separate days. At the first 
visit, subjects gave infonned written consent and were asked about asthmatic symptoms 
and requirement for rescue medication during the past year, especially to avoid the 
inclusion of subjects with mild symptoms of asthma in the remission group. For the same 
reason, subjects were asked to complete Juniper's Quality of Life Questionnaire (17), 
which was verified by the investigator on hidden minor symptoms. Also, physical 
examination was performed and eNO and PD2o MCh determined. At Visit 2, scheduled at 
least l dafter Visit 1, subjects underwent an AMP challenge test. At Visit 3, scheduled at 
least 3 d after Visit 2, FEY 1 and FEY 1 reversibility were tested. The sequence and 
intervals were chosen in order to avoid any influence of the AMP challenge on MHh 
responsiveness and/or on FEY 1 ( 18). The maximal time allowed between Visits 1 and 3 
was 3 wk. 
Spirometry 
Short acting Bragonists were not allowed within 8 hours before the test. Flow-volume 
curves were obtained using a Lilly-type pneumotachograph (Masterlab Jaeger, Wiirzberg, 
Germany). The best of three reproducible recordings ofFEV1 was expressed as 
percentage of predicted normal and used for analysis. Reversibility was tested by 
measuring FEY 1 before and 20 minutes after inhalation of 1 rng of terbutaline powder 
(Bricanyl turbuhaler, ASTRA, Lund, Sweden), and expressed as increase in percentage of 
predicted normal. 
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Nitric Oxide 
Based on the recommendations of the European Respiratory Society Task Force (19), 
eNO was measured in exhaled air by means of chemiluminescence (model280 nitric 
oxide analyzer, Sievers, Boulder, CO) with a sensitivity of 0.1 ppb and a detection range 
of< 0.1 - 500,000 ppb. The sampling flow was 0.2 Llmin and the response time 0.2 s. 
Data were displayed continuously on a PC screen, and stored in a computer with a sample 
frequency of 20 Hz for later analysis. The analyzer was calibrated regularly according to 
the manufacturer1s guidelines, employing certified calibration gases containing 0 ppb, 
100 ppb and 9 ppm NO (Hoekloos, Barendrecht, the Netherlands). The measurement 
circuit consisted of a mouthpiece connected to a two-way nome breathing valve (Hans 
Rudolph, Kansas City, MO), through which subjects inhaled ambient air (if ambient NO 
was < I 0 ppb) or NO-free medical air (if ambient NO was > 10 ppb) while seated, not 
wearing a noseclip. Subjects inhaled to TLC and immediately exhaled for as long as 
possible into a tube with an in-line flow resistor (20 em H20 L-1 s-1, Hans Rudolph). This 
was done at a flow corresponding to 5 % of subject vital capacity per second, with the aid 
of a visual feedback display. A fine-bore Teflon tube continuously sampled exhaled air 
from a side port situated directly after the mouthpiece to the analyzer. Water vapor was 
absorbed by means of an NO-inert filter in the tube. Airflow was measured with a Lilly-
type pneumotachograph (Masterlab Jaeger) positioned downstream of the resistor. An 
end-expiratory plateau of at least 10 s, where flow varied± I 0 % of the target flow, was 
the end point of the measurement. The test was done in triplicate and average eNO at the 
plateau calculated by means of custom-made software. 
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Methacholine and Adenosine-5'-MonoPhosphate Challenge 
Challenge tests were performed at the same time of day(± 1 h) according to the 
dosimeter method validated by Birnie and coworkers (20). Short acting B2-agonists were not 
allowed within 8 h before the test. Calibrated DeVilbiss 646 nebulizers (DeVilbiss Health 
Care, Somerset, PA) were filled with 3 ml of the appropriate solutions. Subjects inhaled four 
5-).ll volumes, using a French-Rosenthal dosimeter (Laboratory for Applied Immunology, 
Fairfax, VA). After recording baseline values, the challenge started with inhalation of 0.9 % 
NaCl. If a patient responded to saline or the lowest concentration of either MCh or AMP, 
they were assigned a PD2o value of half the starting dose. Inhalation provocation tests were 
performed using doubling concentrations of 0.15 to 78.4 mg/ml MCh bromide in phosphate-
buffered saline (PBS) or 0.08 to 160 mg/ml AMP in normal saline (Sigma, St. Louis, MO). 
Provocative doses causing a 20 % fall in FEV 1 (PD2o) from baseline were calculated by 
means of linear interpolation of the logarithmic dose-response curve. IfFEV1 fell less than 
20 % of the pre-challenge level at the highest dose administered, twice the highest dose was 
arbitrarily used as the PD2o value. An MCh PD2o value of 1,000 ].lg, corresponding 
approximately with 7.8 J.liDOl cumulative, was considered the cutoff value for bronchial 
hyperresponsiveness to MCh. 
Peak Expiratory Flow Rate (PEFR) 
After being instructed by the investigator at visit 1, the patients recorded their peak 
expiratory flow rate (PEFR) with a Personal Best peakflow meter (Respironics, Nantes, 
France) twice daily at home during the period benveen Visit 1 and Visit 3. PEFR was 
58 
Chapter 3 Elevated Exhaled NO and BHR during remission 
always recorded before bronchodilatation. Each measurement consisted of three attempts of 
which the highest value was used for further analysis. 
Statistical Analysis 
Because of their highly skewed distributions, PD20 and eNO values were analyzed after 
logarithmic transformation. Mean data were expressed as geometric mean e ± SEM (lnX)_ 
With respect to PD20 values, comparisons between groups were made by the Mann-\Vhitney 
test for unpaired samples. Correlation between different tests was made by the Speannan 
rank correlation test. The distributions of all other variables were not significantly different 
from a standard normal distribution. Hence, parametric techniques (Student t test, Pearson 
correlation coefficients) were applied. Mean values of these parameters were expressed as 
means± SEM. A two-tailed p value ofless than 0.05 was considered significant. Data were 
analyzed with the Statistical Package for the Social Science (SPSS, Chicago, IL) for 
Windows version 8.0. 
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RESULTS 
Sixty subjects completed the study (21 subjects with current asthma, 21 subjects in 
clinical remission and 18 healthy controls). The male-to-female ratio was 15 to 6 in the 
asthmatic group, 18 to 3 in the remission group, and 10 to 8 in the control group. Age did 
not differ significantly between the groups (22 ± 2 yr in the asthmatic group, 21 ± 2 yr in the 
remission group and 24 ± 1 yr in the control group). Duration of remission in the remission 
group varied from I to 12 yr (median, 5 yr), All subjects of the asthma group and the 
remission group, and t:\vo subjects of the control group, had positive RAST tests. Results of 
eNO measurement, bronchial provocation tests and spirometry are summarized in Table 1. 
TABLE L Exhaled NO and pulmonary function 
Asthmatics Clinical Remission Controls 
(n~21) (n~21) (n~JS) 
eNO (ppb) 22e-"U.V* 14e ± o.l5 * le-" u. I 
PD, MCH (~g) 94e=D.37 * 752e ± 031 ** 4,954 · e"' 0 
PD, AMP (~g) l,llOe"' OJ/* 5,704e ± o.n *** 10,496e"' 0 
FEY 1 (% of predicted) 88 ± 12 * 93 ± 15 t 105 ± 13 
Reversibility FEY1 (%) 11 ±I* 7± 1 tt 4±1 
Diurnal PEFR variation(%) 13±2 ll± l 8±1 
Abbreviations: PD20 MCH: provocative dose of methacholine causing a 20% fall in FEY 1• PD10 AMP: 
provocative dose of adenosine-5' -monophosphate causing a 20 % fall in FEY 1. Reversibility FEY 1: change in 
FEY], expressed as increase in% of predicted normal value after administration of I mg terbutaline. 
eNO, PD2o MCH and PD20 AMP are expressed as geometric mean· e ± SEM(lnXJ. 
All other variables are expressed as mean± SEM. * p < 0.001 versus healthy controls.** p < 0.001 versus 
healthy controls and asthmatics.*** p < 0.01 versus healthy controls and asthmatics. t p = 0.02 versus healthy 
controls. tt p < 0.02 versus healthy controls and asthmatics 
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Exhaled NO Values 
Geometric mean eNO values in the remission group were significantly higher than in 
healthy controls (mean, 18.9 and l.O ppb, respectively; p < 0.001), and slightly but not 
significantly lower than those of asthmatics (2!.9 ppb; p ~ 0.09) (Table l; Figure l ). 
Although there seemed to be a trend toward lower eNO values with longer duration of 
remission, a significant correlation between these variables could not be established. 
Figure 1: Exhaled NO values of currently asthmatic subjects, of subjects in clinical remission of atopic 
asthma, and of healthy controls. Each dot represents one subject. Horizontal bars represent geometric mean 
values. TheY-axis shows NO values logarithmically. 
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Bronchial Challenge Tests 
In the remission group, II of21 subjects had a PD2o MCh ofless than 1,000 )lg, 
compared with none ofthe control subjects. Of the subjects with asthma, 19 of21 showed a 
PD2o MCh value below this leveL PD2o MCh values in the remission group were 
significantly lower than in the control group (geometric mean, 751 and 4,954 ).!g, 
respectively; p < 0,001), but higher than in the group of asthmatics (94 )lg; p < 0,001) 
(Figure 2), 
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Figure 2: PD20 MCh (micrograms, not cumulative) values of currently asthmatic subjects, of subjects in 
clinical remission of atopic asthma, and of healthy controls. Non-responders are arbitrarily given a value of 
twice the highest dose administered. Horizontal bars represent geometric mean values. TheY -axis shows 
PD20 MCh values logarithmically. 
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The AMP challenge showed significantly lower PD2o AMP values in the remission group 
than in the control group (geometric mean, 5,704 and 10,496 ~g. respectively; p < 0.01), but 
higher values in the remission group than in asthmatics (1,110 ~g, p < 0.01) (Figure 3). 
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Figure 3: PD20 AMP (micrograms, not cumulative) values of currently asthmatic subjects, of subjects in 
clinical remission of atopic asthma, and of healthy controls. Non-responders are arbitrarily given a value of 
twice the highest dose administered. Horizontal bars represent geometric mean values. TheY-axis shows PD20 
AMP values logarithmically. 
In subjects in remission and those with asthma, PD2o MCh and PD2o Al\1P were highly 
correlated (r = 0.72, p < 0.001). There was a significant inverse correlation between PD2o 
AMP and eNO (r ~ -0.51; p ~ 0.00 I), while no correlation could be established between 
PD2o MCh and eNO (r ~ -0.25; p ~ 0.1 ). There was no significant relationship between 
fonnerly and currently assessed bronchial responsiveness, or between duration of remission 
and bronchial responsiveness. 
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Spirometry and PEFR 
Baseline FEV 1 values, expressed as percentage of predicted normal value, were 
significantly reduced in subjects in remission compared to healthy control subjects (mean, 
93 and 105 %, respectively; p = 0.02). No significant difference could be detected between 
subjects in remission and subjects with asthma (mean, 88 %). Reversibility in FEV1 was 
significantly different (p < 0.02) between the three groups (mean, 11, 7, and 4% in subjects 
with asthma, subjects in remission and healthy control subjects, respectively). Mean diumal 
PEFR variation was 13% in subjects with asthma, 11% in subjects in remission, and 8% in 
control subjects, and showed no significant difference between the groups. 
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DISCUSSION 
In this study, we demonstrated elevated levels of eNO and airway 
hyperresponsiveness to MCh and AMP in adolescents in long-standing clinical remission 
of atopic asthma. During remission, eNO levels were almost similar to those found in 
subjects with current asthma. There was a significant correlation between eNO values 
and AMP responsiveness, but not between eNO values and MCh responsiveness. A 
significant relationship between duration of remission and degree of abnormalities could 
not be established. 
Studies regarding completely symptom-free subjects who had well-documented atopic 
asthma in the past are scarce (6). In our study, subjects were regarded to be in clinical 
remission when they reported complete absence of symptoms and were without treatment 
for at least one yr before the study. This definition was applied to avoid the inclusion of 
asthmatic subjects with mild symptoms in the remission group. The possibility that 
subjects with mild symptoms were included in other studies on asthma remission cannot 
be ruled out. In one of these studies, asthma was considered inactive when subjects 
reported no asthma attacks or use of medication during the preceding year, and were 
without frequent episodes of shortness of breath with wheezing (5). Following this 
definition of remission, the investigators reported bronchial hyperresponsiveness to MCh 
with or without airflow obstruction in subjects aged 18 - 61 years in remission. 
Despite the relatively long median duration of remission, we found that subjects in 
clinical remission had significantly elevated eNO levels, as compared with eNO levels 
from healthy controls. Exhaled NO originates from several inflammatory cell types in the 
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airways, including epithelial- and endothelial cells and macrophages. Whether elevated 
eNO levels are caused by enhanced activity of inflammatory cells expressing NOS, 
potentially driven by inflammatory mediators or cytokines, and/or by enhanced diffusion 
through the airway wall due to structural damage remains to be resolved. An increasing 
number of papers shows evidence that eNO is related to atopic asthma more than to non-
atopic asthma or atopy per se. It was recently demonstrated that atopic asthmatic children 
had higher geometric mean eNO levels than non-atopic asthmatic children, atopic non-
asthmatic children, or non-atopic non-asthmatic children, suggesting that both atopy and 
asthma are important in the context of elevated eNO levels (21). In other studies 
performed recently, eNO levels were significantly higher in atopic subjects with asthma 
compared with levels from non-atopic asthmatic subjects (22, 23). Similar results were 
obtained in patients with rhinitis, whereas no difference was found in eNO levels between 
atopic and non-atopic control subjects (22). Horvath and Barnes found elevated eNO 
levels in atopic asymptomatic subjects, but suggested that this finding merely reflected an 
early stage of airway inflammation, possibly preceding the onset of asthmatic symptoms 
(24). In our study, two subjects in the control group had positive RAST test, but had no 
elevated eNO values. Thus, with reference to the suggestion of Horvath and Barnes, the 
presence of elevated eNO levels in our atopic remission group might well be due to 
subclinical airway inflammation. This is also supported by other studies in which a 
positive correlation was reported between eNO levels and markers of eosinophilic airway 
inflammation in induced sputum (8, 25). Others demonstrated an association between 
eNO and exposure to relevant allergens (26), or a reduction in eNO following 
antiinflammatory treatment (27). These study results provide sufficient indications that 
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airway inflammation is significantly associated with elevated eNO levels, thus providing 
a tool in monitoring disease activity. However, a range of normality needs to be 
established. 
The eNO levels measured in this study tend to be somewhat lower than those 
measured in other studies (8, 28). This may be caused by technical factors. It has been 
shown that there is a marked flow-dependence of eNO values with lower values 
measured at high flow-rates and vice versa (29). We standardized the expiratory flow as 
5% of vital capacity per second, which resulted in an expiratory flow of approximately 
0.25 to 0.30 ml/min, which is higher than the flow used in some other studies. It is not 
clear whether such standardization of flow for lung volume is important when measuring 
eNO. Recently it was demonstrated that the flow-eNO relationship differed between 
asthmatic subjects and healthy individuals (30). This difference is, however, of minor 
importance compared to the differences we now report between the various groups. 
We believe that responsiveness to AMP may serve as indicator of airway 
inflammation, although normal values for bronchial AMP responses have not been 
determined yet. It was demonstrated a few years ago that experimental instillation of 
AMP into an airway segment caused a prompt reduction in airway caliber, paralleled by a 
significant rise in prostaglandin D2, histamine, and tryptase levels in the lavage fluid, 
suggestive of mast cell degranulation (31 ). Since mast cells are believed to play a 
predominant role in asthmatic airway inflammation, the response to AMP may reflect 
different aspects of inflammation as compared with the bronchial response to direct 
stimuli, such as methacholine or histamine. Results supporting this statement include a 
more pronounced improvement of AMP responsiveness following avoidance of allergen 
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(32), and following antiinflammatory therapy (33), as compared with effect on MCh- or 
histamine responsiveness. In recent years, it has been suggested that an exaggerated 
ainvay response to direct stimuli, like MCh, and abnormal FEVl values, may exist or 
persist independently of"active" airway inflammation (34). Probably, these indices are 
also influenced by irreversible airway damage, caused by airway remodeling (35). Thus, 
being associated with the more slowly responding elements of inflammation within the 
airways. Our finding of a positive correlation between response to AMP and eNO levels, 
but not between responsiveness to MCh and eNO levels, is in agreement with this. 
The clinical relevance of our findings is as yet unknown. Although one would expect 
the degree of abnonnalities to be related to the duration of remission, a significant 
correlation could not be established. Probably, when subclinical airway inflammation is 
present during adolescence, it may persist for several years with a continuous risk to 
become clinically manifest again. Future longitudinal studies should assess the possible 
benefits of prolonged disease monitoring and antiinflammatory treatment during the 
asymptomatic phase. Also, the question arises whether or not indices associated with 
different parts of the inflammatory process, such as eNO and responsiveness to AMP and 
MCh, need to be included in the definition of asthma remission. 
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ABSTRACT 
Symptoms of atopic asthma often disappear around puberty. However, asthmatic 
subjects in clinical remission will frequently have a relapse later in life. The aim of this 
study was to investigate whether subjects in clinical remission of atopic asthma have 
persistent airways inflammation and/or airways remodeling. Bronchial biopsies were 
obtained from subjects in clinical remission, asthmatic subjects, and healthy controls. The 
presence and/or activation state of eosinophils, mast cells, rnacrophages, T lymphocytes, 
interleukin (IL)-5, eotaxin and inducible nitric oxide synthase (iN OS) were analyzed. 
Results were compared with less invasive indicators of airways inflammation. Also 
aspects of airways remodeling were determined. 
Eosinophils, T cells, mast cells, and IL-5 were significantly elevated in the airways 
mucosa of subjects in remission compared to controls. Also, blood eosinophil cell counts 
were significantly higher in subjects in clinical remission. Blood eosinophil cell counts, 
exhaled nitric oxide ( eNO) levels, and bronchial response to adenosine-5 '-
monophosphate (AMP) correlated significantly with the quantity of tissue eosinophils. 
Significant ainvays' remodeling was found in subjects in clinical remission. 
In conclusion, our study shows ongoing airways inflammation and airways remodeling 
in adolescents in clinical remission of atopic asthma. Subclinical airways inflammation 
may well determine the risk of an asthma relapse later in life. 
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INTRODUCTION 
Symptoms of atopic asthma often begin in early childhood and mostly improve or 
even seem to disappear around puberty (1, 2). However, a considerable proportion of 
asthmatic subjects in clinical remission will have a relapse later in life (2). Several studies 
have shown spirometric abnormalities and bronchial hyperresponsiveness (BHR) to 
methacholine (MCh) or cold air challenge during clinical remission of asthma (3, 4). It is 
unlmown whether these functional abnormalities, which are supposed to be indicative of 
asthma severity with respect to symptomatic asthma, reflect persistent activity of the 
airways inflammatory process or merely indicate structural changes of the airways as a 
consequence of childhood asthma. These structural changes, known as airways 
remodeling, are probably early events in the course of the disease which appear to 
progress. The process of remodeling leads to thickening of the airway wall (5-7). The 
exact physiologic consequences of airway wall thickening are, however, incompletely 
understood (8). If airway wall thickening is present in subjects in clinical remission of 
asthma, it could at least in part account for the functional abnormalities including 
bronchial hyperresponsiveness found during 'remission'. On its turn, ongoing 'active' 
airways inflammation could have substantial impact on the risk of a relapse later in life. 
As a consequence, subjects with subclinical airways inflammation could benefit from 
anti-inflammatory treatment (8-10). Recently we demonstrated elevated exhaled nitric 
oxide (eNO) levels and BHR to both MCh and adenosine-5'-monophosphate (AMP) 
during clinical remission of atopic asthma (11). With respect to eNO, increased 
expression of the inducible form of nitric oxide synthase (iNOS) is thought to underlie 
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these elevated eNO levels (12, 13). Studies regarding the precise relationship between 
iN OS expression and eNO are, however, scarce (12). 
Proof of persistent airways inflammation and remodeling during clinical remission 
could be furnished from the analysis of bronchial biopsy specimens. Evidence has been 
accumulated to suggest that allergen-reactive type 2 T helper (Th2) cells, with 
eosinophils and mast cells as main effector cells, orchestrate asthmatic airways 
inflammation ( 14, 15). The presence of eosinophils in the airway wall is apparently the 
most reliable feature of bronchial asthma that seems to be related to asthma severity ( 16). 
Along with interleukin (IL)-5, a Th2 cytokine, and eotaxin, a chemoattractant for 
eosinophils, eosinophil-derived products such as major basic protein (MBP) have been 
investigated as markers of eosinophil participation in the pathogenesis of asthma (17). 
Also, elevated numbers of bronchial mast cells have been found in the airway mucosa of 
atopic and non-atopic asthmatic subjects (18, 19). Release of mediators from mast cells, 
such as granule-associated tryptase and chymase, leads to immediate bronchoconstriction 
and enhances airways inflammation ( 19). 
In healthy ainvays, the inflammatory response to e.g. inhaled allergens is suppressed by 
alveolar macrophages. In asthma, however, a deviant function of alveolar macro phages 
may contribute to the allergic immune response in the ainvays (20). 
How numbers and activation state of these different cell types in the bronchial mucosa 
relate to less invasive markers of ainvays inflammation, including bronchial 
hyperresponsiveness (BHR), circulating eosinophils and eNO, is largely unclear (21-23). 
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Remodeling of the ainvays mucosa and submucosa can be assessed by measurement of 
the reticular basement membrane (RBM) thickness (24) and extent of epithelial shedding 
(25). Also, collagen deposition (26) is a quantifiable aspect of airways remodeling. 
To establish whether subjects in clinical remission of atopic asthma suffer from ongoing 
active ainvays inflammation and/or airways remodeling, we compared bronchial biopsy 
specimens of subjects with a long-standing clinical remission of atopic asthma with those 
of currently asthmatic subjects, and of healthy controls. Biopsy findings were compared 
to noninvasive markers of ainvays disease. 
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SUBJECTS, MATERIALS AND METHODS 
Subjects 
Adolescents with atopic asthma, 18- 25 years of age, were selected from the Sophia 
Children's Hospital discharged patients files. Clinical remission of atopic asthma was 
defined as reported complete absence of asthmatic symptoms in subjects not taking any 
asthma medication for at least 12 months prior to the study. Eligible subjects were 
compared with patients with asthma who had persistent symptoms and used inhaled 132-
agonists on demand in order to relieve symptoms. All subjects were previously diagnosed 
as having atopic asthma according to ATS criteria (27). All subjects were lifelong non-
smokers in stable clinical condition and did not take inhaled steroids or anti-allergic 
medication. Healthy non-smoking adult volunteers without a history of asthma served as 
controls. 
The study was approved by the Medical Ethics Committee of the Erasmus Medical 
Center Rotterdam. 
Study design 
We performed a cross-sectional study with three visits on separate days. Spirometry 
values, eNO, MCh- and AMP responsiveness were obtained according to methods we 
described earlier ( 11 ). 
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Blood eosinophils 
Venous blood eosinophil numbers were counted by means ofhemocytometry. 
Reference values ranged from 0.04 to 0.1 x 109 cells/liter. 
Bronchoscopy 
An experienced bronchoscopist (SEO) using an Olympus model BF IT 10 (Tokyo, 
Japan) performed flexible bronchoscopy. At least five bronchial biopsies were obtained 
from segmental divisions of the main bronchi. 
Processing of bronchial biopsies 
Bronchial biopsies were embedded in Tissue-Tek II OCT medium (Miles, Naperville, 
Illinois), snap frozen in liquid nitrogen, and stored at -80°C. Serial tissue sections (6 J..Lm) 
were cut on a HM-560 cryostat (Microm, Heidelberg, Germany). At least two sections 
120 !J.rn apart from one biopsy specimen were placed on a poly-L-lysine-coated 
microscopic slide (Sigma Diagnostics, St.Louis, MO). lmmunostaining was carried out 
with a-CD4 (T helper cells), a-CDS (cytotoxic T cells), a-CD25 (activated cells) and a-
CD69 (activated cells), a-CD68 (macrophages), a-MBP (Dako, Glostrup, Denmark), a-
IL-5, a:-eotaxin, a-tryptase, a-chymase (Chemicon Bnmschwig Chemie, Amsterdam, the 
Netherlands), a,-iNOS (Santa Cruz Biotechnology, Santa Cruz, CA), and a-collagen Ill. 
Binding of the antibodies was detected by the immune-alkaline phosphatase anti-
alkaline phosphatase (APAAP) method. Immunostained sections were analyzed with an 
image analysis system (Quantimed, Leica, Rijswijk, the Netherlands). With respect to the 
sub-epithelium, the program was set to analyze 100 ).lm below the reticular basement 
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membrane (RBM). The ratio of positive stained area divided by the total area analyzed 
was taken as measure for each immunohistochemical staining. RBM thickness was 
interactively measured at 20 ~m intervals over a 1 mm RBM length (24). The occupancy 
ofRBM with epithelium was plotted as ratio of occupied membrane length divided by the 
total membrane length. 
Statistical analysis 
Because of the skewed distribution of data, results are expressed as median value± SEM. 
Comparisons between groups were made by the Mann-\Vhitney test for unpaired samples. 
Correlation between different indices was made by Spearman's rank correlation test. A two-
tailed p-value of equal to or less than 0.05 was considered significant. Data were analyzed 
using Statistical Package for the Social Science (SPSS, Chicago, USA). 
79 
Chapter 4 Persistent airways inflammation during remission 
RESULTS 
Fifty-four subjects completed the study (19 subjects with atopic asthma, 18 subjects in 
clinical remission of atopic asthma, and 17 healthy controls). Subjects characteristics are 
summarized in table 1. The median duration of clinical remission was 5 years. 
TABLE l: Sub"ects' characteristics 
Asthmatic subjects Remission subjects Healthy controls 
N 19 18 17 
Age (years) 22± 2 21 ::::2 24:::: I 
Sex (male: female) 13:6 15:3 9:8 
FEY 
1 
(% of predicted) 88 ± 12 93 ± 15 105 ± 13 
FEY 1 reversibility 11 ± 1 7=1 4±1 
Variables arc expressed as mean::::: SEM. 
Reversibility FEV 1: change in FEY~, expressed as increase in% of predicted normal value after 
administration of 1 mg terbutaline 
Immunohistochemistry results are summarized in table 2. 
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TABLE 2: Immunohistochemistry results 
Asthmatic subjects Remission subjects Healthy controls 
Epithelium 
MBP 0.023 ± 0.0093' 0.0082 ± 0.0046* 0.0007±0.0013 
Tryptase 0.0068 ± 0.0020t 0.0119±0.0029* 0.0025 ± 0.0009 
Chymase 0.0100 ± 0.0035 0.013 ± 0.0030t 0.0067 ± 0.0016 
CD4 0.001 ± 0.0004 0.0007 ± 0.0002 0.0009 ± 0.0013 
CDS 0.025 ± 0.0045 0.018 ± 0.0068 0.0281 ± 0.0082 
CD25 0.0093 ± 0.0050 0.0123 ± 0.0032 0.0058 ± 0.0039 
CD69 0.0095±0.0116 0.0076 ± 0.0182 0.0123 ± 0.0093 
CD68 0.029 ± 0.0054 0.038 ± 0.0067 0.031 ± 0.019 
1L-5 0.038 ± 0.0097 0.036±0.018 0.017±0.014 
Eo tax in 0.001 ± 0.0013 0.0002 ± 0.0045 0.0002 ± 0.0005 
rNOS 0.12±0.02tt 0.15 ± 0.03 0.21 ± 0.03 
Collagen III 0.078 ± 0.011 0.077 ± 0.024 0.062 ± 0.009 
Sub-epithelium 
MBP 0.12 ± 0.026* 0.07 ± 0.024* 0.0042 ± 0.0086 
Tryptase 0.037 ± 0.0082tt 0.075 ± 0.012** 0.022±0.010 
Chymase 0.014 ± 0.0038 0.018 ± 0.0056t 0.0069 ± 0.0033 
CD4 0.0043 ± 0.0040 0.0025±0.0019 0.0041 ± 0.0027 
CDS 0.022 ± 0.0040 0.014±0.0033 0.019±0.004 
CD25 0.0094 ± 0.0126 0.0356 ± 0.0233t 0.0095 ± 0.0041 
CD69 0.0062 ± 0.0198 0.0156 ± 0.0273 0.0085 ± 0.0063 
CD68 0.058 ± 0.0069 0.069±0.013 0.079 ± 0.032 
1L-5 0.025 ± 0.0061 0.022 ± 0.0074** 0.0066 ± 0.0081 
Eo tax in 0.0011 ± 0.0006t 0.0001 ± 0.0087 0.0001 ± 0.0003 
!NOS 0.041 ± 0.006 0.042 ± 0.0141 0.065 ± 0.016 
Collagen III 0.16±0.014 0.19±0.016 0.17±0.019 
Variables are expressed as median density (ratio of positively stained area and total area)± SEM. * p::::: 0.001 
versus healthy controls, ** p::::: 0.01 versus healthy controls, t p::::: 0.05 versus healthy controls, tt p::::: 0.05 
versus remission subjects. 
In both epithelium and sub-epithelium, MBP density was significantly higher in subjects 
in remission than in healthy controls (p<O.OOl and p=O.OOl, respectively; figure 1 and 2). 
81 
Chapter4 Persistent airways inflammation during remission 
10 
p < 0.001 
8 
p < 0.001 
= 
== ~
;§ 
"' 
0,1 ~ 
0 • 
• ~ "t ~ 
• 0,01 ..... ~ 
Q. I 
"' i :;: 0,001 I 
-
0,0001 
Asthma Remission Controls 
(n = 19) (n =18) (n= 17) 
10 
s p < 0.001 
= ·~ p = 0.001 
-
" 
-= • ;<::: 
• • ... 
" + ' 0,1 • I ..Q 
-= 
• • ~ 
... • • 
.-:: I • ~ 0,01 • • 
= I ... 
" 
"" I ~
=:i 0,001 • 
~ • • 
• 
0,0001 
Asthma Remission Controls 
(n ~ 19) (n ~ 18) (n ~ 17) 
Figure 1: ratio of area of Major Basic Protein (MBP) staining and total area of epithelium (upper figure) 
and of sub-epithelium (lower figure) in bronchial biopsy specimens from currently asthmatic subjects, 
subjects in clinical remission of atopic asthma, and healthy controls. Each dot represents one subject. 
Horizontal bars represent median values. Y -axis shows values logarithmically. 
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Figure 2: Bronchial biopsy specimen from a healthy control subject (a) and a subject in clinical remission 
of atopic asthma (b), immunostained with a-Major Basic Protein (MBP). Notice the increased MBP-
positive area (the red stain) and epithelial shedding in the subject in clinical remission. 
In bronchial epithelium of subjects in remission, there was more tryptase present than 
in that of healthy controls {p=0.001). In sub-epithelium, however, there was more 
tryptase detectable in subjects in remission than in control subjects and in patients with 
asthma (p~O.OOS and p~0.025, respectively; figure 3 and 4). 
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Figure 3: ratio of area oftryptase staining and total area of epithelium (upper figure) and sub-epithelium 
(lower figure) in bronchial biopsy specimens ffom currently asthmatic subjects, subjects in clinical 
remission of atopic asthma, and healthy controls. Each dot represents one subject. Horizontal bars represent 
median values. Y-axis shows values logarithmically. 
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aL_ ____________________________ ~ 
Figu re 4: Bronchial biopsy specimen (a-tryptase) from a healthy control subject (a) and a subject in 
clinical remission of atopic asthma (b). Notice the increased tryptase-positive area (the red stain) and 
epithelial shedding in the subject in clinical remission. 
Chymase density was higher in bronchial epithelium and sub-epithelium of subjects in 
remission than in that of healthy controls (p=0.044 and p=0.05, respectively). 
There was no difference detectable in the presence of CD4+ and CDS+ cells in both 
epithelium and sub-epithelium among the experimental groups. However, there were 
more activated, CD25+ cells present in the sub-epithelium of subjects in remission 
compared to control subjects (p=0.04). No such difference was detected for CD69. 
CD68+ cells were equally represented in sub-epithelium and epithelium in all three 
experimental groups. 
In sub-epithelium, lL-5 density was significantly higher in subjects in remission than in 
healthy controls (p=0.006). Eotaxin density was significantly higher in patients with 
asthma than in healthy controls (p=0.05), while intennediate levels were detected in 
subjects in remission. In the epithelium, densities of fL-5 and eotaxin were similar in all 
three groups. Density ofiNOS was s ignificantly higher in sub-epithelium of healthy 
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subjects than in that of subjects in remission (p~0.05). In the epithelium, iN OS density 
was higher in healthy subjects than in asthmatic subjects (p~0.05). No difference in iNOS 
density could be detected between healthy control subjects and subjects in clinical 
remission. 
With respect to indices of remodeling, RBM thickness differed significantly between 
subjects in remission and control subjects (10.9 ± 1.3 and 7.9 ± 1.0 ).UTI, respectively; 
p<O.OO 1 ). Current asthmatic subjects showed a median thickness of 11.5 ± 1.5 J.Lm 
(Figure 5). 
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Figure 5: Thickness of the reticular basement membrane (REM) in biopsy specimens from currently 
asthmatic subjects, subjects in clinical remission of atopic asthma, and healthy controls. Horizontal bars 
represent median values. 
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Furthermore, in subjects in remission the RBM occupancy with epithelium differed 
significantly from values obtained from control subjects (ratio 0.67 and 0.83, 
respectively; p<0.003), and from values from current asthmatic subjects (median ratio 
0.50, p<0.03) (Figure 6). 
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Figure 6: Occupancy of the reticular basement membrane (RBM) with epithelium in biopsy specimens 
from currently asthmatic subjects, subjects in clinical remission of atopic asthma, and healthy controls. 
Results are plotted as ratio of the length of occupied RBM divided by the total membrane length. 
Horizontal bars represent median values. 
Collagen type III density in biopsy specimens was not significantly different between the 
groups. In peripheral blood, the number of eosinophils was significantly elevated in 
subjects in remission compared with control subjects (0.22 ± 0.17 x 109/l and 0.11 ± 
0.045 x 10911, respectively; p<O.OOl; figure 7). Median eosinophil count in patients with 
asthma was 0.30 ± 0.17 x 109/l. 
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Figure 7: Eosinophil cell counts in blood samples from currently asthmatic subjects, 
subjects in clinical remission of atopic asthma, and healthy controls. Each dot represents 
one subject Horizontal bars represent median values. 
In subjects in remission and those with asthma, a significant positive correlation was 
found between blood eosinophil cell counts and MBP density in both bronchial 
epithelium and sub-epithelium (r=0.41, p=O.Ol7 and r=0.45, p=0.009, respectively; figure 
Sa). A similar correlation was observed for eNO values (11) and MBP density in 
bronchial epithelium and sub-epithelium of subjects in remission and patients with 
asthma (r=0.40, p=0.022 and r=0.35, p=0.043, respectively; figure Sb). 
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Figure 8: Correlation between blood eosinophil cell count and Major Basic Protein (MBP) density in sub-
epithelium (r=0.45. p=0.009) (upper figure), and bet\veen exhaled Nitric Oxide (eNO) and MBP density in 
the bronchial epithelium (r=0.40, p=0.022) (lower figure) in the population of subjects in remission and 
currently asthmatic subjects. Each dot represents one subject. 
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PD2o AMP values correlated inversely with MBP density in sub-epithelium of subjects in 
remission and subjects with asthma (r=-0.37, p=0.032). In contrast, no significant 
correlation could be found between PD2o MCh values and MBP density in bronchial 
biopsy specimens. In subjects in remission and those with asthma, thickness of the RBM 
correlated with PDzo AMP (!=0.47, p~0.038), whereas the relationship with PDzo MCh 
was not significant (!=0.36, p~O.l). 
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DISCUSSION 
In this study we demonstrated the presence of an ongoing active inflammatory process 
in the ainvays during long-lasting clinical remission of atopic asthma, as reflected by 
significantly increased levels ofMBP, tryptase, chymase, CD25 and IL-5 in bronchial 
epithelium and/or sub-epithelium. In addition, eosinophil cell counts in blood samples 
were significantly elevated during clinical remission compared with those in healthy 
control subjects. Less invasive indicators of airways inflammation, such as blood 
eosinophils, eNO and PD20 AMP showed a significant correlation with MBP density in 
biopsy specimens from subjects in remission and patients with asthma. We also found 
evidence of airways remodeling during clinical remission. There was a significant 
correlation between RBM thickness and bronchial hyperresponsiveness to AMP. 
Airways inflammation has been demonstrated in subjects with symptomatic asthma 
(28, 29). However, studies regarding the presence of inflammation in bronchial biopsy 
specimens from prolonged symptom-free subjects with a history of atopic asthma are 
lacking. Therefore, we applied a strict definition of clinical remission, where subjects 
were regarded in clinical remission if they reported complete absence of cough, chest 
discomfort or breathlessness for at least one year preceding the study, and did not use any 
medication in order to control asthma symptoms. In our study population, the median 
duration of remission was 5 years with only one subject that had been in remission for 
just one year. Not withstanding these strict inclusion criteria, we are the first to show 
direct evidence of substantial active airways inflammation, suggesting persistent disease 
in these otherwise asymptomatic subjects. 
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Increased numbers of eosinophils, one of the most important effector cells in atopic 
asthma, have been demonstrated in the bronchial mucosa of patients with asthma ( 17). 
We present similar findings in the bronchial mucosa of subjects in clinical remission. 
Also, elevated levels of tryptase- and chymase, constituents and markers of mast cells, 
were detected in the bronchial mucosa of subjects in remission compared to those of 
healthy controls. On the other hand, we found reduced tryptase density in the airway wall 
mucosa of subjects with asthma as compared with subjects in remission. This is 
suggestive of enhanced degranulation of mast cells in patients with asthma compared to 
subjects in clinical remission. Upon degranulation, mediators are diluted out into the 
tissue environment and rapidly degraded (30). 
In the ainvay mucosa, there was no significant difference between the groups with 
respect to the presence ofT cells. In previous studies, elevated T cell numbers where 
found in the ain.vay mucosa, even in patients newly diagnosed with asthma (31 ). Others 
reported no increase in total numbers ofT cells in bronchial mucosa specimens (32, 33), 
or just an increase in activated T cell numbers (34, 35). We found elevated levels of 
CD25 expression in bronchial sub-epithelium of subjects in remission compared to 
healthy subjects, which was not demonstrated in patients with asthma. The number of 
CD69+ cells was not elevated. In our study, patients with asthma were in stable phase of 
disease and by definition the subjects in remission were without clinical symptoms all 
together. Therefore, disease activity should be regarded low in both groups. This may 
explain the absence of significantly elevated density ofT cells. However, we did find 
increased levels of activated cells albeit not with an early marker of activation. 
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We found similar CD68 levels in all three groups. This may indicate that total 
macrophage numbers are relatively unimportant for asthma, and that a transformed and 
activated subset of these cells may be responsible for disease activity (20). 
The relationship between markers of inflammation in bronchial biopsy specimens and 
other indices that presumably reflect distinct aspects of the inflammatory process, 
including peripheral blood eosinophils, eNO and the degree of BHR to various inhaled 
stimuli, is controversiaL It has been proposed that determination of numbers of 
eosinophils in peripheral blood may help to indicate the level of airways inflammation 
(23). In the present study, blood eosinophil numbers correlated significantly with ainvay 
mucosal MBP density. Therefore, blood eosinophil cell numbers might serve as an 
indicator of eosinophilic ainvays inflammation in otherwise symptom free subjects with a 
history of atopic asthma. 
A relationship between elevated cell numbers and/or cell activity in bronchial biopsy 
specimens and BHR has been demonstrated in some other studies (22, 36). Especially 
BHR with AMP as the inhaled stimulus has been proposed as a useful marker reflecting 
at least part of the inflammatory process in asthma (37). We found a significant 
correlation between PD2o AMP and MBP density in the ainvay wall mucosa in patients 
with current asthma and subjects in clinical remission of asthma. However, such a 
correlation could not be established between PD20 MCh values and MBP density in the 
ainvay mucosa. This is in agreement with other reports where MCh responsiveness 
appeared to be unrelated to indices of inflammation determined in bronchial biopsy 
specimens, and more to structural changes of the ainvays (21, 38). Previously, we 
reported that levels of eNO were significantly correlated with PD2o AMP, but not with 
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PD2o MCh (11). This is in agreement with finding that both PD,o AMP and eNO are 
related to the activity of cells known to play a role in the inflammatory process in asthma. 
In contrast, MCh acts directly on smooth muscle (SM) cells in the airway walls. 
Therefore, the response to MCh potentially reflects the structural changes found in 
asthma (39). This is supported by the fact that bronchial hyperreactivity to MCh may 
exist independently of active airways inflammation ( 40). The fact that MCh acts directly 
on SM cells may explain the absence of a correlation between BHR to MCh and RBM 
thickness. On the other hand, the positive correlation between BHR to AMP and RBM 
thickness may be explained by the presumed contribution of inflammatory mediators to 
the process of RBM remodeling. 
Although epithelial desquamation may be an artifact of tissue sampling and not a true 
pathologic feature of the disease (41 ), we were able to demonstrate that the denudation of 
the RBM is much more progressive in patients with asthma than in subjects in remission. 
In subjects in remission, denudation is more pronounced than in healthy control subjects. 
We hypothesize that the severity of airways disease determines the susceptibility of the 
epithelium for physical stress. Hence, the differences we observed between the groups 
may be a reflection of the overall integrity of bronchial epithelium in the asthmatic 
bronchus compared to the bronchus of subjects in remission and to that of healthy control 
subjects. 
Exhaled NO levels have already been shown to correlate with blood- and sputum 
eosinophilia in atopic children and adults with mild-intermittent asthma (42-44). Our 
study is the first to show a significant correlation between eNO levels and airway 
eosinophilia, as reflected by MBP density in the ain.vay mucosa. Recently, eNO levels 
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were reported not to correlate with mucosal eosinophils ( 45). This difference may be 
explained by methodological factors, which include patient selection and -numbers. 
Surprisingly, we found enhanced iNOS density in the ainvay wall mucosa from 
healthy controls compared with asthmatics and subjects in remission. This is not in 
agreement with the hypothesis of increased expression of iN OS in airway epithelium as 
the cause of elevated eNO (12, 46). We speculate that iN OS unrelated mechanisms, 
including enhanced diffusion of NO through damaged epithelium, or iNOS independent 
NO generation under conditions of airway acidity (47) may explain this finding in 
subjects with airways inflammation. Furthermore, other isofonns of NOS could account 
for elevated NO production. Following an increase in NO, a negative feedback 
mechanism might result in lower iN OS levels in the airway mucosa from asthmatic 
subjects. 
In conclusion, our study shows ongoing airways inflammation and airways remodeling 
in adolescents in clinical remission of atopic asthma. We speculate that subclinical 
airways inflammation may well determine the risk of asthma relapse later in life. 
Furthermore, we hypothesize that subjects with evidence of airways inflammation during 
"remission" could possibly benefit from anti-inflammatory treatment in the short- and/or 
long-term. We propose that blood eosinophils, eNO and airway responsiveness to AMP, 
each reflecting distinct parts of the inflammatory process, may be useful in the long-term 
monitoring of asthmatic airways inflammation. 
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ABSTRACT 
Symptoms of atopic asthma often disappear around puberty. We recently 
demonstrated that this clinical remission is accompanied with ongoing ainvays 
inflammation in most subjects. The discrepancy between lack of symptoms and persistent 
airway inflammation suggests blunted perception of symptoms. In the present study, 
young adults in clinical remission of atopic asthma assigned themselves a modified 
BORG score during methacholine and adenosine-5' -monophosphate induced 
bronchoconstriction. BORG scores of subjects in clinical remission were compared with 
those of symptomatic asthmatic subjects. We found a marked variation in BORG scores 
at 20% fall in FEV J. Significant differences in BORG scores between remission patients 
and asthmatics could not be detected. We conclude that perception of dyspnea, induced 
with methacholine- and adenosine challenge, is similar in young adults in clinical 
remission of atopic asthma compared to that of patients with symptomatic asthma. Hence, 
blunted perception seems to be an unlikely explanation for the discrepancy between lack 
of symptoms and ongoing inflammation. Other factors, which include physical and 
psychological ones, may play a role in the apparent absence of symptoms, thereby 
potentially leading to undertreatment. 
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INTRODUCTION 
In asthma, symptoms often decrease or even seem to disappear around puberty. 
Unfortunately, clinical remission is followed by a relapse later in life in a considerable 
proportion of subjects (1, 2). We recently found ongoing airways inflammation during 
clinical remission of atopic asthma (3, 4). Persistent airways inflammation during clinical 
remission would possibly explain the high relapse rate. The relationship between dyspnea 
perception and other indices of asthmatic severity, such as the degree of 
bronchoconstriction, is poor (5, 6). Conversely, impaired dyspnea perception is especially 
believed to play a role in severe asthma (7-9). Poor perception of airflow obstruction may 
lead to undertreatment of asthma (1 0). Especially in view of the high relapse rate of 
asthma later in life, diminished perception of dyspnea in subjects in clinical remission of 
asthma is of great clinical relevance. Therefore, the hypothesis of our study was that 
subjects in clinical remission of atopic asthma have blunted perception of dyspnea. 
Dyspnea scores, including visual analogue scale (VAS) scores and (modified) BORG 
scores, can be assessed during spontaneous asthma or during induced bronchoconstriction 
(11). The aim of the present study was to compare dyspnea scores during induced 
bronchoconstriction between young adults in clinical remission of asthma and currently 
symptomatic asthmatic subjects. Since the mechanism ofbronchoconstriction differs 
between direct stimuli (methacholine, MCh) and indirect stimuli (adenosine-
monophosphate, AMP), and may give rise to different perception, , MCh as well as AMP 
challenges were used in both groups. 
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SUBJECTS, MATERIALS AND METHODS 
Subjects 
Young adults with atopic asthma, 18 - 25 years of age, were selected from the Sophia 
Children1s Hospital discharged patients files. Clinical remission of atopic asthma was 
defined as reported complete absence of cough, wheezing and breathlessness at rest and 
on exertion in subjects not taking any asthma medication for at least 12 months prior to 
the study. Approximately 80 percent of subjects in clinical remission showed elevated 
nitric oxide levels, eosinophilic airway inflammation, and hyperresponsiveness to both 
MCh and AMP (3, 4). All subjects responding with a 20 percent fall in FEV1 during 
induced bronchoconstriction with MCh or AMP were considered eligible for the present 
study. Ten eligible subjects in remission were included, and compared with ten patients 
with asthma who had persistent symptoms, assessed with theSF-36 quality of 
life/symptom score form, at least once a month in the year preceding the study, and used 
inhaled ~2-agonists on demand in order to relieve symptoms. Subjects with current 
asthma could thus be defined as having 'mild persistent asthma' according to GINA 
guidelines. All subjects had a history of wheezing and chest tightness and were 
previously diagnosed as having asthma according to ATS criteria (12). All were atopic 
defined as radio allergosorbent test (RAST) class 2 or higher for at least one common 
airborne allergen. All subjects were lifelong non-smokers in stable clinical condition and 
did not take inhaled steroids, including nasal steroids, or anti-allergic medication like 
cromoglycate and antihistamines for at least one year prior to the study. 
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Common exclusion criteria were an inability to perfonn lung function tests reproducibly, 
and illnesses that may affect lung function. None of the subjects in the study reported 
symptoms of respiratory infection in the month prior to the study. 
The study was approved by the Medical Ethics Committee of the Erasmus University 
Medical Center Rotterdam. 
Study design 
We per fanned a cross-sectional study with two visits on separate days. At the first 
visit, subjects gave informed written consent and were asked about their asthmatic 
symptoms, history and requirement of rescue medication during the past year. Also, 
physical examination was performed, followed by determination of MCh responsiveness. 
At the second visit, scheduled at least l day after visit l, subjects underwent an AMP 
challenge test. During the tests, subjects were asked to score their degree of 
breathlessness after each dose given according to a modified BORG scale. The sequence 
and intervals of the provocation tests were chosen in order to avoid any influence of the 
AMP challenge on MCh responsiveness (13). 
Methacholine and Adenosine-5'-MonoPhosphate challenge 
Challenge tests were performed at the same time of day (± 1 hour) according to the 
dosimeter method as described in detail earlier (3, 14). Short acting ~ragonists were not 
allowed within 8 hours prior to the test. If a patient responded to saline or the lowest 
concentration of either MCh or AMP, they were assigned a PDzo value of half the starting 
dose. Inhalation provocation tests were performed using doubling concentrations of 0.15 to 
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78.4 mg/ml MCh bromide in PBS or 0.08 to 160 mg/ml AMP in normal saline (Sigma 
Chemical Co., St. Louis, MO). During MCh and AMP challenge, before each FEV1 
measurement, perception of dyspnea was assessed on a modified BORG scale. A perception 
score at 20 percent fall in FEV1 (PS2o) was obtained by interpolation of the two last points 
on the perception/fall in FEV1 curve (10). 
Statistical analysis 
Data are expressed as mean PS2o ± SEM. Comparisons between groups were made by 
Student's t-test for unpaired samples. A two-tailed p-value of less than 0.05 was considered 
significant. Correlation was expressed as partial correlation coefficient. Data were analyzed 
using Statistical Package for the Social Science (SPSS, Chicago, USA) for \Vindows TM 
version 9.0. 
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RESULTS 
Twenty subjects could be assigned both a PS2o MCh value and a PS2o AMP value (10 
subjects with currently symptomatic atopic asthma and 10 subjects in clinical remission 
of asthma). 
Subjects' characteristics are summarized in table I. The two groups were comparable 
with respect to age, FEY 1, and PD2o AMP. PD2o MCh in currently symptomatic asthmatic 
subjects was significantly lower than in subjects in clinical remission (p=0.034). 
TABLE 1: Subject's characteristics 
Asthmatic subjects 
n 
10 
Age (range) 22.5 (19-25) 
Sex (male : female) L3 
FEV 1 (range) 90 ± 3 (80- 1 06) 
PD2o MCh (range) 0.4 ± 0.3 (0.1 - 2.8) 
PD20 AMP (range) 5.3 ± 2.3 (0.6- 27.3) 
Remission subjects 
10 
20.6(19-24) 
10' 0 
91±4(63-107) 
2.3 ± 1.1 (0.1 -9.9) 
9.8 ± 2.6 (1.0- 22.0) 
All subjects, including the ones in clinical remission, experienced some degree of 
dyspnea at reaching a 20 percent decrease in FEV 1, even though there was a marked 
within-group variation in PS20 (for instance 0.5 to 9 in the remission group with respect to 
MCh provocation). Nevertheless, for both inhaled stimuli no significant difference 
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between currently asthmatic subjects and subjects in clinical remission with respect to 
PS,o could be detected (Figure 1 and 2). 
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Figure 1: PS20 MCh values in subjects with asthma and subjects in clinical remission of atopic asthma. 
Each dot represents one subject. Horizontal bars represent median values. 
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Figure 2: PS20 AMP values in subjects with asthma and subjects in clinical remission of atopic asthma. 
Each dot represents one subject. Horizontal bars represent median values. 
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Mean PS,oMCh was 2.7 ± 1.1 (range 1-4) and 3.2 ± 2.5 (range 0.5-9) for currently 
asthmatic subjects and subjects in remission, respectively, and 3.3 ± 1.3 (range 1-5) 
versus 3.7 ± 1.9 (range 0.5-6) with respect to AMP induced bronchoconstriction. We did 
not find a significant relationship between bronchial responsiveness, expressed as PD20, 
and respiratory distress at reaching a 20 percent decrease in FEY 1 for both inhaled stimuli 
(r=0.23 and p~0.34 for MCh; r=0.06 and p~0.81 for AMP; figure 3 and 4). 
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Figure 3: Partial correlation coefficients 
between PD20 and PS20 with respect to MCh 
challenge in currently asthmatic subjects (o) 
and subjects in clinical remission of atopic 
asthma (•). 
Figure 4: Partial correlation coefficients 
between PD20 and PS20 with respect to AMP 
challenge in currently asthmatic subjects (o) 
and subjects in clinical remission of atopic 
asthma ( • ). 
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DISCUSSION 
In this study we did not find significant differences in dyspnea perception between 
currently asthmatic subjects and subjects in clinical remission of atopic asthma at 20 
percent fall in FEV1 with MCh and AMP induced bronchoconstriction. MCh 
responsiveness differed significantly between subjects in remission and currently 
symptomatic asthmatics, whereas AMP responsiveness did not. All subjects experienced 
some degree of dyspnea at reaching a 20 percent fall in FEY 1• Dyspnea scores varied 
from 'very, very slight dyspnea' to 'almost extreme dyspnea'. A signi'ficant correlation 
between dyspnea perception and degree of bronchial hyperresponsiveness could not be 
detected. 
The finding that MCh-, but not AMP responsiveness differs significantly between 
subjects in clinical remission and currently asthmatic subjects, can be explained by a 
difference in mechanism of action. Where MCh responsiveness may be influenced by 
structural changes in the airways and active airway inflammation, AMP is believed to 
reflect only active airway inflammation, including increased numbers of mast cells. Thus, 
since currently asthmatic subjects may suffer from both more pronounced structural 
changes and more active inflammation, as compared with subjects in remission, MCh 
responsiveness may well separate the groups better than AMP responsiveness. 
In 1994, Boulet and coworkers suggested that lack of symptoms may be insufficient as 
a tool to determine that asthma is in true remission (15). Indeed, there is a weak 
correlation between symptoms on the one hand and bronchial hyperresponsiveness and 
airways inflammation on the other. Several investigators have pointed to the possibility 
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of diminished perception of dyspnea in subjects with more severe grades of asthma, 
potentially leading to undertreatment in these subjects (7-9). Such an inverse relationship 
is not a consistent finding ( 1 0). Also in our study, there was no correlation between 
dyspnea perception and PD2o. However, our study population had a limited range of 
asthma severity. 
Reduced dyspnea perception during clinical remission could possibly explain the 
absence of symptoms despite persistent airways inflammation and bronchial 
hyperresponsiveness (4) found in these subjects. Studies concerning symptom perception 
in asymptomatic asthmatics are scarce. In the present study we included subjects in 
clinical remission of atopic asthma supposedly having no grade of asthma at alL Given 
the ongoing airways inflammation we recently documented in a considerable proportion 
of those subjects (3, 4), it seemed of the greatest importance to show whether diminished 
perception of symptoms is present. The results of the present study do not confirm that 
blunted symptom perception explains the lack of symptoms. Subjects in clinical 
remission are obviously capable to detect ainvay narrowing at a similar level as 
compared with currently asthmatic subjects. On the other hand, others found a poor 
relationship between perception of spontaneous' daily life' asthma and artificially induced 
bronchoconstriction (I 0, II). It can therefore not be excluded that this is also true for 
subjects in clinical remission of asthma. Thus, it might still be possible that, as a result of 
biomechanical, pathophysiological or psychological factors, abnormal daily life 
fluctuations in airflow are not interpreted as asthma by subjects in clinical remission (6, 
16). A fast decline in FEV 1 as a result ofMCh or AMP induced bronchoconstriction is 
probably less liable to interindividual differences, and thus could explain the present 
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findings. Nevertheless, since dyspnea and other asthmatic symptoms seem to be an 
interplay between the degree of asthmatic inflammation and many other influences 
including physical and psychological factors ( 6, 7), we suggest that the absence of 
asthmatic symptoms in subjects regarded as ex-asthmatics should be interpreted with 
great care. 
In conclusion, our study indicates that the lack of symptoms despite persistent 
bronchial hyperresponsiveness and ongoing airways inflammation during clinical 
remission of asthma seems not to be due to blunted symptom perception. Other factors, 
which include physical and psychological ones, may play a role in the apparent absence 
of symptoms in daily life. This is a potential factor leading to undertreatment. 
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ABSTRACT 
Symptoms of atopic asthma often disappear around puberty. In 30 to 80% of the 
subjects with apparently outgrown asthma, however, symptoms will recur later in life. 
This high relapse rate is possibly due to ongoing airway inflammation and remodeling 
during clinical remission. We hypothesized that a-symptomatic subjects with ongoing 
airway inflammation and remodeling may benefit from anti-inflammatory treatment. 
A double-blind, randomized placebo-controlled trial was conducted in 28 subjects in 
clinical remission of atopic asthma with bronchial hyperresponsiveness to methacholine 
(MCh) as non-invasive indicator of ongoing airway inflammationlremodeling. 
Intervention consisted of the salmeterol/fluticasone propionate combination product 
(SFC 50/250 !Jg bid via the DiskusTM inhaler) or placebo for three months. The change 
in lung function (FEV 1), bronchial response to MCh and adenosine monophosphate 
(AMP), the fraction of nitric oxide in exhaled air (FENO), and quality of life scores 
were measured. Also, bronchial biopsies were taken and cryo sections immunostained 
for eosinophils (major basic protein; MBP) and mast cells (tryptase and chymase) 
before and after treatment. The change in reticular basement membrane (RBM) 
thickness, one of the parameters of airway remodeling, was also detennined. 
SFC treatment improved PD,0 MCh (p~0.014) as well as PD2o AMP (p~O.O!I), and 
reduced FENO (p<O.OOl) significantly. Furthennore, SFC treatment reduced tryptase in 
the subepithelium of bronchial biopsy specimens (p~O.OI), and slightly reduced RBM 
thickness (p=0.05). However, eosinophils in (sub)epithelium were affected not 
significantly, as were chymase levels, blood eosinophils and quality of life scores. 
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In conclusion, we found that three months of treatment with combination therapy with 
fluticasone propionate and salmeterol improved airway hyperresponsiveness and FENO 
as non-invasive markers of airway inflammation, but had limited effect on inflammation 
in bronchial biopsies. Long-tenn clinical trials are needed to show benefits in terms of a 
reduced risk of relapse and/or of irreversible airflow obstruction later in life. If that 
proves to be the case, anti-inflammatory therapy during clinical remission of atopic 
asthma could be justified. 
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INTRODUCTION 
Atopic asthma commonly starts in childhood and often seems to disappear in early 
adolescence (1, 2). Unfortunately, a substantial proportion of asthmatic adolescents with 
apparently outgrown asthma will have a relapse later in life, mostly before the age of 30 
(2). Recently we and others found markers of airway inflammation and structural airway 
changes in airway biopsy specimens and bronchoalveolar lavage (BAL) fluid from young 
adults with a longstanding clinical remission of atopic asthma (3, 4). Ongoing 
inflammation and remodeling possibly contribute to irreversible airway narrowing (5) 
and bronchial hyperresponsiveness, thereby providing a basis for a future relapse of 
asthma. 
It is unclear whether the long-term prognosis of subjects in clinical remission of 
asthma can be altered with prolonged anti-inflammatory therapy. There is ample evidence 
that inhaled steroids decrease airway inflammation (6), whereas the effect on remodeling 
is less evident (7, 8). An effect on subepithelial collagen deposition (9) and airway wall 
vascularity (10) was, however, found. Hence, the question arises whether subjects in 
clinical remission of atopic asthma could benefit from anti-inflammatory treatment (9, 
11, 12). When it comes to "optimal" treatment of moderate to severe asthma, there is a 
strong scientific rationale for combining inhaled steroids with long-acting ~2-agonists. 
(13, 14). Therefore, it was the aim of this study to investigate the effect of a short course 
of such asthma treatment on indices of airway inflammation and remodeling in young 
adults in longstanding clinical remission of atopic asthma. 
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SUBJECTS, STUDY DESIGN AND METHODS 
Subjects 
Young adults, 18- 30 yrs of age, were selected from the Sophia Children1s Hospital 
discharged atopic asthma patients files. Clinical remission of atopic asthma was defined 
as reported complete absence of asthmatic symptoms while not taking any asthma or 
allergy medication for at least 12 mo prior to the study. All subjects were previously 
diagnosed as having atopic asthma according to ATS criteria (15). All subjects were 
lifelong non-smokers in stable clinical condition. We conducted a double blind, parallel-
group, randomized placebo-controlled trial in 28 subjects who were in clinical remission 
of atopic asthma for a median duration of 5 yrs, with a PD2o methacholine (MCh) 
cumulative less than or equal to 7.8 Jlmol at the beginning of the study. 
The study was approved by the Medical Ethics Committee of the Erasmus Medical 
Center Rotterdam. 
Study design 
All subjects underwent non-invasive and invasive measurements on 3 visits within 3 
wks, followed by a 3-months' intervention period, after which all measurements were 
repeated on 3 visits. At the first visit, subjects gave written informed consent and were 
asked about asthmatic symptoms and requirement of rescue medication during the past 
yr, especially in order to avoid the inclusion of subjects with mild asthma. Also, quality 
of life scores were obtained. Thereafter, physical examination was performed and the 
fraction of NO in exhaled air (FENO) and PD20 MCh determined. At visit 2, scheduled at 
least 1 day after visit 1, subjects underwent an AMP challenge test. At visit 3, scheduled 
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at least 3 days after visit 2, FEY 1 and FEY 1 reversibility were tested. The sequence and 
intervals were chosen in order to avoid any influence of the AMP challenge on MCh 
responsiveness and/or on FEV 1 (16). All baseline measurements were used to obtain the 
subjects' characteristics (table 1 ). For further analysis on a specific variable, only subjects 
with pre- as well as post-treatment values (table 2 and 3) were used. 
Spirometry values, MCh- and AMP responsiveness, FENO and blood eosinophils 
were obtained according to methods we described earlier (17). These are summarized 
briefly hereafter. Methods of obtaining quality oflife scores as well as collecting and 
processing bronchial biopsies are described in more detail. Intervention consisted of the 
salmeterol/fluticasone propionate combination product (SFC 250/50 ~g bid via the 
Diskus™ inhaler) or placebo for 3 mo ± 2 wks. Therapy adherence and adverse effects 
were recorded by the primary investigator. If more than 85 percent of the totally 
prescribed number of doses \Vas emptied out of the device, therapy adherence was 
arbitrarily considered adequate. 
Bronchial hyperresponsiveness 
Challenge tests were performed according to the dosimeter method validated by Birnie 
and coworkers ( 18). Study medication was not allowed within 36 hrs prior to the test. After 
recording baseline values, the challenge started with inhalation ofNaCl 0.9 %. Inhalation 
provocation tests were performed using doubling concentrations of0.15 to 78.4 mg/ml MCh 
bromide in PBS or 0.08 to 160 mg/ml AMP in nonnal saline (Sigma Chemical Co., St. 
Louis, MO, USA). Cumulative provocative doses causing a 20% fall in FEV1 (PD2o) from 
baseline were calculated by means of linear interpolation of the logarithmic dose-response 
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curve. IfFEV1 fell less than 20% of the pre-challenge level at the highest dose 
administered, twice the cumulative total inhaled dose was arbitrarily used as the PD20 value. 
Spirometry 
Study medication was not allowed within 36 hrs prior to the test. Flow-volume curves 
were obtained using a Lilly-type pneumotachograph (Masterlab Jaeger, Wlirzberg, 
Gennany). The best of3 reproducible recordings ofFEV 1 was expressed as percentage of 
predicted normal and used for analysis. Reversibility was tested by measuring FEY 1 
before and 20 minutes after inhalation of 1 rng of terbutaline powder (Bricanyl 
turbuhaler, ASTRA, Lund, Sweden), and expressed as increase in percentage of predicted 
normal. 
FENO 
FENO was measured in exhaled air by means of chemiluminescence (model280 nitric 
oxide analyser, Sievers, Boulder, CO) according to recommendations of a European 
Respiratory Society Task Force (!9). Subjects inhaled to TLC and immediately exhaled for 
as long as possible into a tube with an in-line flow resistor (20 em H20/Lisee, Rudolph, 
MO). This was done at a flow corresponding to 5% of the subjects' vital capacity per 
second. 
Bronchoscopy 
Premedication consisted ofterbutaline 1 mg by metered dose inhalator and atropine 
500 f.Lg intramuscularly. After topical anesthesia with oxybuprocaine I Omg/ml to a 
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maximum of20 ml, and xylocaine 10%, an Olympus model BF IT 10 (Tokyo, Japan) was 
passed by oral route. All bronchoscopies were performed by the same pulmonary 
physician (S.E.O.) At least 5 bronchial biopsies were obtained with the Olympus Swing 
Jaw forceps from segmental divisions of the main bronchi at both occasions. 
Processing of bronchial biopsies 
Bronchial biopsies were embedded in Tissue-Tek II OCT medium (Miles, Naperville, 
Illinois), snap frozen in liquid nitrogen, and stored at -80°C. Serial tissue sections (6 !-liTI) 
were cut on a HM-560 cryostat (Microm, Heidelberg, Germany). At least two sections 
120 Jlm apart from one biopsy specimen were placed on a poly-L-lysine-coated 
microscopic slide (Sigma Diagnostics, St.Louis, MO). Jmmunostaining was carried out 
with o:-major basic protein (MBP, Sanbio BV, Uden, the Netherlands), o:-tryptase and o:-
chymase (Chemicon Brunschwig Chemic, Amsterdam, the Netherlands). Binding of the 
antibodies was detected by the immuno-alkaline phosphatase anti-alkaline phosphatase 
(APAAP) method. Immunostained sections were analyzed with an image analysis system 
(Quantimed, Leica, Rijswijk, the Netherlands). With respect to the sub-epithelium, the 
program was set to analyze 100 f-Un below the RBM. The ratio of positive stained area 
divided by the total area analyzed was taken as measure for each immunohistochemical 
staining. RBM thickness was interactively measured at 20 ~m intervals over a 1 mm 
RBM length (20). 
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Quality of life 
Quality of life scores were obtained with the aid of a modified RAND Health 
Insurance Study Questionnaire (21 ), the so-called RAND 36-item Health Survey, Dutch 
Version. RAND 36 consists of eight different categories of general health, that is to say 
physical functioning, social functioning, role limitations, emotional problems, mental 
health, pain, general health perception and health change. Items are scored I to 5 or 6. A 
higher score means better health. In each category, 100 is the maximum total score. 
Statistical analysis 
Lung function data (FEY1, FEY 1 reversibility, PD20 MCh and PD20 AMP) and quality 
of life data (RAND 36) were parametrically analyzed using ANCOYA, where the 
baseline measurement of the outcome variable considered was included as covariant in 
comparing the two treatment groups (SFC and placebo). Within-subject changes from 
baseline of these variables were tested using the paired t-test for either treatment group. 
For the PD20 variables, the analyses were done after log2 transformation. PD20 MCh was 
used as primary variable. The other outcome variables were analyzed by comparing 
changes from baseline between the two treatment groups using the Mann-Whitney test 
Within-subject changes from baseline of these other variables were tested using the 
"Wilcoxon signed rank test for either treatment group. P-values below 0.05 were supposed 
to denote statistical significance. 
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RESULTS 
Both the salmeterol/fluticasone propionate combination (SFC) group and the placebo 
group consisted of 14 subjects. Groups were well matched with respect to age, sex, FEY 1, 
FEV 1 reversibility, bronchial response to MCh and AMP and FENO (table 1). One 
subject in the placebo group refused the second bronchoscopy because of a negative 
experience with the first one. One other subject, also in the placebo group, could not 
undergo bronchoscopy because of a bleeding disorder. Therapy adherence was adequate 
since none of the subjects had used less than 85 percent of the prescribed total number of 
doses. Both treatments were well tolerated. 
TABLE 1: Subjects' characteristics 
SFC Placebo 
n(male) 14(11) 14 (9) 
Age (yr) 19.6 (18- 23) 20.4(18-24) 
FEV1 (% pred) 94.1 (63 -119) 101.2 (87- 120) 
FEY 
1 
reversibility(%) 9.9(0-31) 6.9 (0- 23) 
PD::>o MCh (!J-mol) 1.7 (0.1 - 6.2) 3.3 (0.3- 7.4) 
PD20 AMP (~uno!) 24.0 (1.0- 60.5) 23.1 (1.4-60.5) 
FENO (ppb) 11.9 (7.2- 22.0) 9.5 (4.0-23.4) 
SFC: salmeterollfluticasone propionate combination.All variables but FENO (median; range) are expressed as 
means (range). FENO: Fraction of nitric oxide in exhaled air. 
SFC treatment for three months significantly improved PD2o MCh (p~O.Ol4, table 2, 
fig 1) as well as PD20 AMP (p~O.Oll, table 2, fig 2), and reduced FENO (p<O.OOl, table 
2, fig 3). Furthennore, SFC treatment reduced tryptase-positive cells in the bronchial 
subepithelium (p~O.Ol, table 3, fig 4 and 5), whereas MBP-positive cells in both the 
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epithelium and subepithelium decreased slightly, but not significantly (table 3, fig 6). 
Following SFC treatment, thickness of the RBM was reduced slightly (p~0.05, table 3, 
fig 7). Compared to placebo, FEV 1 and FEV 1 reversibility, blood eosinophils, chymase 
density and quality of life scores did not change as a result of three months of SFC 
treatment. Results are summarized in table 2 and 3. 
TABLE 2: Results pre- and post-treatment- non-invasive measurements 
SFC Placebo Significance (p) 
FEY 1 pre (% pred) 93.9 ± 4.6 (13) 101.5±2.7(13) 
NS 
FEY 1 post(% pred) 99.9 ±2.7 (13) 101.7 ± 3.7 (13) 
FEV 1 reversibility pre(%) 10.5 ± 2.9 (13) 6.5 ± 1.8 (13) 
NS 
FEY 1 reversibility post(%) 4.7 ± 1.7 (13) 6.2 ± 1.2 (13) 
PD20 MCh pre (!J.mol) 1.7 ± 0.5 (14) 3.3 ± 0.7 (14) 
0.014 
PD-20 MCh post ()-lmol) 19.8 ±4.8 (14) 6.3 ±2.9 (14) 
PD20 AMP pre (J.unol) 24.0 ± 6.6 (14) 23.1 ± 5.7 (14) 
0.011 
PD::w AMP post (!.uno!) 44.8 ± 6.0 (14) 27.6 ± 6.9 (14) 
FENO pee (ppb) 13.0 ± 1.4 (12) 9.5 ± 1.5 (12) 
<0.001 
FENO post (ppb) 4.9 ± 1.8 (12) 10.8 ±2.2 (12) 
Quality of life pre 89.9±4.2(12) 84.5 ± 4.3(13) 
NS 
Quality oflife post 88.2 ± 4.5 (12) 79.8 ± 3.9 (13) 
SFC: salmeterol/fluticasone propionate combination. Pre: pre-treatment. Post: post-treatment. FENO: Fraction 
of nitric oxide in exhaled air. All variables but FENO (median± SEM) are expressed as means± SEM. 
Number of subjects between brackets. NS: not signiftcant. 
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TABLE 3: Results pre- and post-treatment -blood and biopsy measurements 
SFC 
Blood eosinophils pre (x 109/1) 0.3 ±0.05 (12) 
Blood eos post (x 109/1) 0.4±0.07 (12) 
MBP subepithelium pre* 0.016± 0.005 (II) 
MBP subepithelium post* 0.008 ± 0.008 (II) 
MBP epithelium pre* 0.017 ±0.003 (11) 
MBP epithelium post* 0.006 ± 0.006 (11) 
Tryptase subepithelium pre * 0.012 ± 0.004 (I 0) 
Tryptase subepithe\ium post* 0.004 ± 0.001 (1 0) 
Tryptase epithelium pre* 0.003 ± 0.0008 (10) 
Tryptase epithelium post* 0.0009 ± 0.0009 (1 0) 
Chymase subepithelium pre* 0.002 ± 0.001 (7) 
Chymase subepithelium post* 0.0009 ± 0.003 (7) 
Chymase epithelium pre* 0.001 ± 0.0003 (7) 
Chymase epithelium post* 0.001 ± 0.0005 (7) 
RBM thickness pre ().lm) 9.7 ± 0.8 (8) 
RBM thickness post (!lm) 8.7 ± 1.3 (8) 
SFC: salmeterol!fluticasone propionate combination. 
Placebo 
0.3 ± 0.08 (12) 
0.3 ± 0.08 (12) 
0.008 ± 0.005 (11) 
0.009 ± 0.009 (11) 
0.014 ± 0.004 (11) 
0.017 ± 0.008 (11) 
0.005 ± 0.002 (11) 
0.005 ± 0.005 (11) 
0.001 ±0.001 (11) 
0.004 ± 0.001 (11) 
0.004 ± 0.001 (9) 
0.003± 0.001 (9) 
0.0009 ± 0.0009 (9) 
0.001 ± 0.0009 (9) 
9.1 ±0.4 (11) 
9.0 ± 1.1 (11) 
Significance (p) 
NS 
NS 
NS 
0.01 
NS 
NS 
NS 
0.05 
*The ratio of positive stained area divided by the total area analyzed was taken as measure for 
immunohistochemical stainings. Pre:pre-treatment. Post: post-treatment. 
RBM: thickness of the reticular basement membrane (~m). 
Values are expressed as medians± SEM. Number of subjects between brackets. NS: not significant. 
123 
Chapter 6 Benefit from anti-inflammatory treatment 
50 
45 sfc placebo 
• 
40 
> p=0.014 ] 35 
, 
E 30 , 
u 
0 25 
E 
"' 
20 ~ 
<..> 
" 
15 
,5 
10 0. 
5 
0 
p•e post p•e post 
Figure 1: Cumulative PD::>o MCh values pre- and post-treatment for three months \Vith the 
salmeterol!fluticasone propionate combination product (sfc, n=14)) or placebo (n= 14). Each line represents 
one subject. Non-responders are arbitrarily given a value of twice the highest cumulative dose given. 
Horizontal bars represent mean values. 
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Figure 2: Cumulative PD20 AMP values pre- and post-treatment for three months with the 
salmeterollfluticasone propionate combination product (sfc, n=l4 )) or placebo (n= 14). Each line represents 
one subject. Non-responders are arbitrarily given a value of twice the highest cumulative dose given. 
Horizontal bars represent mean values. 
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Figure 3: FENO pre- and post-treatment for three mo with the salmeterollfluticasone propionate 
combination product (sfc, n=l2) or placebo (n=l2). Each line represents one subject. Horizontal bars 
represent median values. 
a b 
Figure 4: Example of a biopsy specimen pre-(4a) and post-treatment (4b) from a subject in clinical 
remission with tryptase staining (mast cells) in red. 
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Figure 5: Tryptase density in the bronchial subepithelium pre- and post-treatment for three months \Vith the 
salmeterollfluticasone propionate combination product (sfc, n= I 0) or placebo (n= 11 ). Each line represents 
one subject. Horizontal bars represent median values. 
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Figure 6: MBP density in the bronchial subepithelium pre- and post-treatment for three months with the 
salmeterollfluticasone propionate combination product (sfc, n= 11) or placebo (n= 11 ). Each line represents 
one subject. Horizontal bars represent median values. 
NS: not significant. 
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Figure 7: Thickness of the reticular basement membrane (RBM) pre- and post-treatment for three months 
with the salmeterol/fluticasone propionate combination product (sfc, n=8) or placebo (n=ll ). Each line 
represents one subject. Horizontal bars represent median values. 
NS: not significant. 
127 
Chapter 6 Benefit from anti-inflammatory treatment 
DISCUSSION 
Many subjects in clinical remission of atopic asthma have ongoing ainvay 
inflammation and remodeling (3, 4), which may predispose for a relapse later in life. The 
present study shows that combined treatment with an inhaled steroid and a long-acting 
Bz-agonist significantly reduced bronchial hyperresponsiveness and FENO levels, 
whereas invasively obtained markers of inflammation and remodeling remained largely 
unchanged. 
Anti-inflammatory treatment normalized both MCh responsiveness and AMP 
responsiveness in a substantial proportion of the subjects in the present study. Where 
AMP responsiveness is believed to be related to active airway inflammation by inducing 
mast cell degranulation, MCh acts through direct mechanisms on the airway smooth 
muscle, thereby at least in part reflecting structural changes, i.e. airway remodeling, in 
the airways (22). We recently found a significant relationship between AMP 
responsiveness and eosinophilic airway inflammation (3). Hence, a nonnal response to 
AMP suggests the absence of clinically significant active inflammation (23). Normal 
MCh responsiveness, on the other hand, relates to the absence of manifest structural 
changes in the airways as well. In a study ofKoh and colleagues, BHR to MCh was 
unchanged in subjects in clinical remission of asthma after nine months of treatment with 
inhaled budesonide (24). Whether this was due to more severe and irreversible airway 
changes, or a different kind of study medication as compared with our treatment, is 
unclear. Thus, next to FENO measurement, both MCh and AMP challenge might be 
useful in monitoring disease activity and response to treatment. 
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A highly significant reduction in FENO levels was seen. More specifically, 10 out of 
12 subjects treated with SFC reached FENO values within the normal range after three 
months of treatment. It has been recently shown that FENO correlates with airway 
mucosal eosinophilia (3, 25), BAL eosinophils (26) and sputum eosinophils in atopic 
asthma (27). Therefore, FENO might be a useful tool in monitoring disease activity and 
effectiveness of treatment (28-30). Our data suggest that FENO might be a more rapidly 
responding marker of active inflammation than are tissue eosinophils. 
With respect to markers of airway inflammation in tissue specimens, only tryptase 
levels improved significantly. Since a central role in the inflammatory process has been 
attributed to bronchial mast cells (31, 32), the demonstrated effect of anti-inflammatory 
therapy on these cells may be of clinical relevance. Changes in MBP density, reflecting 
eosinophil activity, showed a trend towards a reduction in the SFC group, but were not 
significant. We speculate that MBP changes might reach significance when more subjects 
would have been studied. 
We found that the thickness of the reticular basement membrane (RBM), one of the 
characteristics of airn"ay remodeling, was reduced in some subjects, but not in alL Overall 
changes were of borderline significance. It can be argued that these changes may be the 
result of reduction in RBM edema due to plasma leakage (12, 33, 34), which might also 
be influenced by the addition of a long acting f32-agonist (LABA) to the study medication 
(1 0). Ward et al. recently demonstrated a significant effect of fluticasone propionate on 
thickness of the RBM after nine months of treatment in subjects with mild asthma (35). 
Other characteristics of airway remodeling, such as subepithelial collagen deposition and 
smooth muscle hyperplasia, presumably respond more slowly, if at all (8, 9). Therefore, 
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our intervention may have been too short to induce important changes in the RBM 
thickness. 
The choice of salmeterol plus fluticasone propionate was based on the concept of 
optimal combination treatment as therapy of choice in moderate to severe asthma. In 
recent years, an additive or even synergistic effect oflong acting P2-agonists (LABA) on 
airway inflammation (14, 36) and ainvay vascularity (10) has been documented. Also, 
LABA can improve well being by providing immediate relief. As we found no evidence 
of subjective improvement or better quality of life in this study, the added value of the 
long-acting Bragonist in subjects with subclinical asthma remains conceptual. It was, 
however, not the aim of this study to elucidate which treatment would be best for the 
subjects in clinical remission. 
The present study also demonstrates that the improvement in bronchial 
hyperresponsiveness, FENO values and mast cell activation is not accompanied by 
improved quality of life. We previously reported that the perception of acute onset 
airflow obstruction was intact in subjects in clinical remission of asthma (3). Presumably, 
slow changes in the degree of airway inflammation and remodeling are not well 
perceived by asthmatic subjects. Especially in patients with asthma in clinical remission 
or with mild asthma, this has important implications for the way we make treatment 
decisions, as the presence of symptoms is obviously not a sensitive indicator of ongoing 
disease. 
The clinical implications of our study seem to be rather complicated. The effects of 
our intervention on hyperresponsiveness, FENO and tissue mast cells were significant 
and might be beneficial to the patient. Any effect on the long-term prognosis is, however, 
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unclear. Moreover, it is questionable whether subjects who have no subjective benefit 
from treatment will continue to take prescribed inhaled steroids for an unspecified time, 
since adherence with treatment is already a worry in patients with symptomatic asthma. 
Tn conclusion, our data show that three months of combination therapy improved 
ainvay responsiveness and FENO as non-invasive markers of ain:vay inflammation, but 
had limited effect on inflammation in bronchial biopsies, and did not affect quality of life 
scores. Long-tenn controlled clinical trials are therefore needed to show benefits in terms 
of a reduced risk of relapse and/or of irreversible airflow obstruction later in life. If that 
proves to be the case, anti-inflammatory therapy during clinical remission of atopic 
asthma could be justified. 
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ABSTRACT 
Subjects that are believed to have grown out of asthma often develop symptoms again 
later in life. Ongoing airway inflammation may detennine the risk on later relapse, 
although the mechanisms involved remain poorly understood. Additionally, patients with 
childhood asthma may develop irreversible airflow obstruction, i.e. airway remodeling, as 
a result of chronic airway inflammation. Recently both airway inflammation and 
remodeling could be demonstrated in bronchial biopsy specimens from young adults who 
considered themselves grown out of asthma. It is also shown that evidence of airway 
inflammation and remodeling can be obtained non-invasively, thereby providing the 
opportunity to monitor disease activity. lf chronic airway inflammation and/or 
remodeling are consistent findings in asymptomatic subjects with a history of atopic 
asthma, the question arises whether natural history can be positively altered with 
prolonged anti-inflammatory therapy. Such benefit on the long-tenn prognosis is, 
however, as yet not shown. Since epidemiological work has demonstrated that a certain 
percentage of subjects with apparently outgrown atopic asthma remains asymptomatic, 
without needing therapy, for the rest of their lives, it can be argued that "asthma 
remission does exist". The question is whether this percentage can be increased with 
prolonged anti-inflammatory therapy and regular control. 
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INTRODUCTION 
Symptoms of atopic asthma often disappear around puberty (1, 2). Unfortunately, 30 
to 80% of subjects who apparently have grown out of asthma develops symptoms again 
later in life (3). As yet, the underlying risk factors are unknown. Martinez and coworkers 
(4) suggested that chronic airflow limitation may contribute to recurrence of symptoms in 
adult life, even after long periods of clinical remission and especially among active 
smokers. The mechanisms leading to this persistent airflow limitation are, however, 
incompletely understood. Recently some authors have suggested that ongoing airway 
inflammation is the principal cause of progressing airway abnormalities (5, 6) and, 
consequently, the high relapse rate (7, 8). 
In this review certain issues will be discussed, such as the concept that ongoing airway 
inflammation and remodeling coincide during "remission" of asthma. Also the 
discrepancy between ongoing inflammation and the temporary absence of symptoms will 
be dealt with. Finally, the question whether the long-tenn prognosis of asymptomatic 
subjects with persistent inflammation can be altered with anti-inflammatory therapy and 
intensified control is addressed. 
In the last paragraph, we make an effort to answer the question "will asthma ever go 
away" and to propose a strategy for subjects who believe to have grown out of asthma. 
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ONGOING AIRWAY INFLAMMATION DURING CLINICAL REMISSION 
Few studies have looked at asymptomatic subjects with a history of asthma. In 1978 
Kerrebijn et al (9). examined pulmonary function in 24 children who had not received 
treatment for over a year nor had any symptoms of their asthma. Although clinical 
recovery from asthma seemed to be apparent, increased bronchial smooth-muscle tone 
was still present in these children. In 1994, Boulet et al ( 1 0) demonstrated that most of a 
group of30 ex-asthmatics considered to be in asthma remission showed a persistent 
increase in airway responsiveness to methacholine (MCh). It is, however, not clear 
whether these abnonnalities were accompanied by ongoing airway inflammation or were 
solely due to structural changes as a late sequel of childhood asthma. To answer this 
question, we recently performed fiberoptic bronchoscopy in 18 subjects in clinical 
remission of asthma, 19 subjects with symptomatic asthma, and 17 healthy controls (7). 
Biopsies were taken from the subcarinae of the main bronchi. Immunohistochemical 
staining showed a significantly increased density of eosinophils (major basic protein 
staining) and mast cells (tryptase) in the bronchial mucosa of subjects in remission as 
compared with that from healthy controls (figure I and 2). The authors thus demonstrated 
the presence of ongoing inflammation despite the absence of symptoms. 
Recently, Warke and colleagues performed bronchoalveolar lavage (BAL) in 35 nonnal 
children, 10 children with outgrown viral wheeze, and 25 children with outgrown asthma 
(8). They found elevated numbers of eosinophils in the BAL fluid of children who had 
apparently outgrown their asthma compared to controls (p=0.002, figure 3). There was no 
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relationship between the length of remission and degree of airways eosinophilia. They 
speculated that ongoing airway inflammation might be a risk factor for future relapse . 
. · ... 
a .. ·· b 
Figure 1: Major basic protein (MBP) density in a bronchial biopsy specimen from a subject in clinical remission or 
asthma (a) and from a healthy control (b). MBP is stained red. 
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Figure 2: Ratio of area of major basic protein (MBP) staining and total area of sub-epithelium in bronchial 
biopsy specimens from currently asthmatic subjects, subjects in clinical remission of atopic asthma, and 
healthy controls. Each dot represents one subject. Horizontal bars represent median values. 
Van den Toorn et al. 2001; Am J Re.1pir Crit Care Med !64(11):2 107-13. 
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Figure 3: Bronchoalveolar lavage (BAL) t1uid for healthy children, viral wheeze outgrown and atopic 
asthma outgrown. The value marked 0.7 (dashed line) corresponds to the previously defined upper limit of 
nonnal BAL fluid eosinophil%, and the solid lines represent median values.# p=0.002. 
Warke eta!. 2002; Eur Respir J 19(2):284~7. With permission of MD. Shields. 
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AIRWAY REMODELING DURING CLINICAL REMISSION 
The end result of asthmatic ainvay inflammation and its healing processes is an altered 
structure referred to as airway remodeling. This altered airway structure includes fibrosis 
and increased smooth muscle, mucus gland mass, vessel area, thickening of the reticular 
basement membrane (RBM) and epithelial desquamation ( 11 ). As a consequence of these 
structural changes, the airway wall in asthma is usually thickened, which may result in 
permanent airflow obstruction. Cokugras et al demonstrated thickening of the RBM even 
in 9-year old children with moderate asthma (12). Page and colleagues described recently 
how human mast cells from asthmatic patients induce human ainvay smooth muscle 
(HASM) cell proliferation. They proposed that mast cells fulfill a central role in the 
remodeling process ( 13 ), which was also suggested by others ( 14, 15). 
Invasively obtained "proof' of airway remodeling during clinical remission of asthma is 
scarce. In our study, thickness of the RBM in ainvay biopsy specimens from subjects in 
clinical remission of asthma differed significantly from those from healthy controls (7). 
Also, occupancy of the RBM with epithelium differed between the study groups. 
141 
Chapter 7 Asthma remission • Does it exist? 
MONITORING DISEASE ACTIVITY DURING CLINICAL REMISSION 
Since flexible bronchoscopy is not feasible as a routine monitoring tool, non-invasive 
markers that predict the degree of airway inflammation and/or remodeling are needed. 
Possible indices of airway inflammation include the level of sputum eosinophils, the 
presence of bronchial hyperresponsiveness (BHR) to inhaled stimuli, and exhaled nitric 
oxide (eNO) levels. 
In 1995, Fahy demonstrated that analysis of induced sputum in subjects with asthma 
reveals infonnation about eosinophil percentages qualitatively similar to those obtained 
by analysis ofBAL fluid (16). A close relationship between sputum eosinophils and 
eosinophil percentage in BAL fluid could also be demonstrated in a study by 
Grootendorst and colleagues (17). With respect to treatment decisions, Green and Pavord 
could recently demonstrate that a management strategy directed at normalising the 
sputum eosinophil count reduced asthma exacerbations (2002 ATS poster A320), which 
finding for the first time provides "evidence" for the usefulness of monitoring ainvay 
inflammation. 
BHR can be measured with different kind of stimuli. Provocation with adenosine 5'-
monophosphate (AMP), as an indirect ainvay challenge, has been suggested to be a better 
marker of ainvay inflammation than direct challenges, such as provocation with 
methacholine (MCh) (18, 19). Where MCh directly induces smooth muscle contraction, 
AMP is thought to have its effect through the stimulation of bronchial mast cells. The 
presence of mast cells in airway smooth muscle cells has recently been shown to be a 
hallmark of asthma which is highly associated with disordered ainvay function (20). In a 
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study by Van den Berge and coworkers, PC20 MCh and PC20 AMP were measured in 120 
patients with atopic asthma (21 ). In contrast to PC,o MCh, PC2o AMP could be predicted 
by the percentage of eosinophils in sputum. This is in agreement with our findings, where 
the density of mucosal eosinophils correlated significantly with BHR to AMP and with 
eNO levels, but not with BHR to MCh (7). Also when measuring the effect of allergen 
avoidance (22, 23) and of anti-inflammatory therapy (24-26) on airway inflammation, 
PC2o AMP has been proven to be a useful monitoring tool. On the other hand, Sont et a!. 
could demonstrate a significant correlation between PC20 MCh and eosinophil number in 
the lamina propria (27). 
The response to MCh may, thus, provide infonnation about active inflammation as 
well as structural ainvay changes as a consequence of airway remodeling (28-30). In a 
study by Ward et al, it was shown that an early improvement in BHR to MCh with 
fluticasone treatment was associated with early changes in inflammation, but the more 
progressive and larger improvement was associated with later improvement in airway 
remodeling (31 ). 
Recent articles on the subject have evidenced of a close relationship between eNO 
levels and exposure to relevant allergens (32, 33), or allergen avoidance (34) in atopic 
asthmatic subjects. Furthermore, eNO positively correlates with the level of blood- and 
sputum eosinophils in asthmatic subjects (35-37). The observation that eNO levels in 
atopic asthmatic subjects are closely related to the eosinophil percentage in BAL fluid 
(38) and in bronchial biopsy specimens (7, 39) from atopic asthmatic subjects indicates 
sufficiently that elevated eNO levels are highly associated with eosinophilic airway 
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inflammation, thereby providing a unique tool in monitoring disease activity. It also 
seems to be justified to categorise asthma activity with the aid ofeNO levels (40, 41). 
In conclusion, sputum eosinophils, eNO levels and BHR to AMP provide useful tools 
in monitoring disease activity, whereas BHR to MCh may also or merely reflect 
remodeling processes in the airways. 
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SYMPTOM PERCEPTION DURING CLINICAL REMISSION 
Blunted symptom perception would provide a plausible explanation for the 
discrepancy between persistent ainvay inflammation and the absence of symptoms during 
clinical remission. Several studies have shown that the relationship between asthmatic 
symptoms and other indices of asthma severity is poor. Teeter et al. found asthma 
symptoms to correlate poorly with the level of airway obstruction (42). A low degree of 
"perceptiveness 10 for bronchoconstriction is especially demonstrated in subjects with 
severe asthma (43, 44). Bijl-Hofland hypothesized that either patients with more severe 
asthma show adaptation of "perceptiveness" for airway obstruction or, perhaps instead, 
that low perceptiveness leads to more severe asthma as a result ofundertreatment (44). If, 
after years of symptomatic asthma, adaptation or loss of perceptiveness plays a role in 
subjects in clinical remission of asthma, it could possibly explain the discrepancy 
between the lack of symptoms and the ongoing airway inflammation in these subjects. In 
a study from our group, however, BORG-scores after a 20% fall in FEV1 during MCh-
and AMP induced bronchoconstriction were not different between subjects in clinical 
remission and subjects with symptomatic asthma (45), thereby making blunted dyspnea 
perception not a vel)' likely explanation for the stated discrepancy. We suppose that the 
weight given by patients to breathlessness depends on many other factors, including age, 
where younger patients find it more troublesome than older ones ( 46). Besides, a slow 
change in airflow obstruction is possibly less perceived than a fast deterioration due to 
provocation with MCh or AMP. This was also shown by Rietveld, who demonstrated that 
patients with prolonged airway obstruction perceived symptoms less well and were more 
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vulnerable to negative effects of asthma than patients with acute onset airway obstruction 
(47). 
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RATIONALE FOR ANTI-INFLAMMATORY THERAPY DURING CLINICAL 
REMISSION OF ASTHMA 
Since some studies have evidenced of ongoing airway inflammation during clinical 
remission of atopic asthma (7, 8), it has increasingly been a subject of debate that 
prolonged anti-inflammatory therapy should be prescribed to these patients. Since airway 
inflammation is considered the cornerstone of asthma ( 48), inhaled steroids are widely 
accepted as first-choice therapy, even in the mildest fonns of disease (49). A down-
regulating effect on several cell types in the bronchial mucosa (50, 51), sputum 
eosinophils (52, 53), exhaled NO (53, 54) and bronchial hyperresponsiveness (55) has 
been demonstrated. Airway remodeling aspects such as collagen deposition and thickness 
of the RBM have also been shown to respond to some degree to anti-inflammatory 
therapy (56, 57). If airway remodeling corresponds with progressive airway obstruction, a 
smaller decline in lung function with anti-inflammatory therapy could possibly be 
reached, as shown by Grol et al. (58). Several authors have focussed their attention to the 
important concept that with the aid of inhaled corticosteroids natural history and final 
outcome of asthma might be altered (59-61). Koh eta!. studied the effect of inhaled 
budesonide on BHR to MCh of subjects in long-standing clinical remission of asthma 
(62). After nine months of therapy no significant change on BHR was seen in this study. 
It was suggested that the mechanisms underlying BHR in this clinical setting could be 
different from those in symptomatic asthma. As BHR to MCh is in the first place thought 
to reflect structural changes in the airways, the absence of any effect of anti-inflammatory 
therapy on this parameter could be due to irreversible remodeling of the airways in the 
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subjects studied. On the other hand, De Kluijver et al demonstrated that asymptomatic 
worsening of airway inflammation in subjects with mild asthma could be prevented by 
inhaled steroids (63). In a study from our group (64), a significant reduction in bronchial 
hyperresponsiveness, exhaled nitric oxide levels, bronchial mast cells and thickness of 
the reticular basement membrane was seen after three months of combination therapy 
with fluticasone proprionate plus salrneterol in subjects in clinical remission of atopic 
asthma. However, bronchial eosinophils, blood eosinophils, and quality of life were 
unchanged. 
Thus, it is still unclear whether subjects, who seem to have grown out of asthma, but 
show evidence of ongoing disease, would benefit from prolonged anti-inflammatory 
therapy in the long-term. Since several study results indicate that inhaled steroids can 
positively influence progressive airflow limitation and long-term prognosis in 
symptomatic asthmatics, this therapeutic modality should presumably also be (re) 
considered in subjects with subclinical airway inflammation. Whether this approach is 
really able to alter the natural history in subjects in clinical remission of asthma is as yet 
not !mown. Besides, therapy adherence in asymptomatic young adults will presumably be 
a major problem. Long-term controlled clinical trials are therefore needed to show 
benefits in terms of a reduced risk of relapse and/or of irreversible airflow obstruction 
later in life. 
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DOES ASTHMA EVER GO AWAY? 
There is ample evidence from the literature and our own studies that most young 
adults who consider themselves grown out of asthma just appear to be asymptomatic. The 
question remains whether true remission can be achieved, with or without the aid of anti-
inflammatory therapy. It may be that the absence of any signs of airway inflammation 
and airway remodeling is representative of true remission. This was only true for 10 or 15 
percent of our population of asymptomatic subjects with a history of atopic asthma. 
Epidemiological data show that a small percentage of young adults in clinical remission 
remains asymptomatic for the rest of their lives. These may very well be the subjects in 
true remission. It is largely unknown whether "additional remissions" can be achieved 
with prolonged anti-inflammatory treatment, and, if so, when this treatment can safely be 
stopped. Bahceciler and colleagues recently investigated which parameters would be 
useful in deciding whether inhaled corticosteroids therapy could be stopped. They 
demonstrated that only the duration of clinical remission prior to cessation of treatment 
had proven to be a useful parameter ( 65). In addition to their finding, Sont eta! have 
shown that a better control of airway inflammation can be achieved when airway 
hyperresponsiveness is used as additional guide (66). Thus, long-term control at the 
outpatient clinic with non-invasive measurements reflecting airway inflammation and 
remodeling is presumably needed to decide whether anti-inflammatory therapy should be 
started, continued or stopped. 
We propose that adolescents who seem to have grown out of asthma should be monitored 
for years after symptoms have disappeared, thereby using non-invasive measurements of 
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ainvay inflammation and remodeling, such as exhaled nitric oxide levels, sputum 
eosinophils and the response to MCh and/or AMP. Treatment might be safely withheld in 
subjects without signs of airway inflammation or remodeling. In all other patients 
continuation of anti-inflammatory therapy has the theoretical potential to positively alter 
the prognosis of atopic asthma. Long-term studies are needed to examine the efficacy and 
safety of treatment on asymptomatic subjects with chronic airway inflammation. 
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Conclusions and recommendations for future research 
With reference to the questions, postulated in chapter 2, it can be concluded that: 
Ongoing airway inflammation and remodeling can be demonstrated invasively 
and non-invasively in the majority of subjects who are believed to have grown out 
of asthma. 
2 Blunted symptom perception is not a likely explanation for the discrepancy 
between ongoing airway inflammation and absence of symptoms in subjects in 
clinical remission of atopic asthma. 
3 Anti-inflammatory treatment in subjects with subclinical airway inflammation 
reduces bronchial hyperresponsiveness, exhaled NO levels, and bronchial mast 
cells, but the effect on long-term prognosis is as yet not clear. Even so, the value 
of prolonged monitoring of ain:vay inflammation and remodeling during clinical 
remission of asthma has to be elucidated. 
4 True asthma remission seems to be a rare phenomenon. 
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FUTURE RESEARCH 
Long-term controlled clinical trials on prolonged anti-inflammatory therapy in subjects in 
clinical remission of asthma are needed to show benefits in terms of a reduced risk of 
relapse and/or of irreversible airflow obstruction later in life. If that proves to be the case, 
anti-inflammatory therapy during clinical remission of atopic asthma could be justified. 
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In this thesis, the presence of ongoing airway inflammation in subjects in clinical 
remission of atopic asthma is demonstrated. Next to a discussion of non-invasive and 
invasive methods which can be used to produce evidence of ain.vay inflammation, the 
concept of blunted dyspnea perception to explain the discrepancy between absence of 
symptoms and ongoing airway pathology in subjects with apparently outgrown asthma is 
evaluated. Furthennore, the desirability to treat a-symptomatic subjects with ongoing 
disease with anti-inflammatory therapy is dealt with. Finally, an answer is sought to the 
question whether true remission in asthma is possible. 
In Chapter 1, epidemiology and classification of atopic asthma are reviewed. Although 
the presence and extent of symptoms of asthma are the basis of all classification systems, 
it is emphasised that airway inflammation is the hallmark of atopic asthma. An overview 
of non-invasive and invasive methods to evaluate ainvay inflammation in asthma, with 
the bronchial biopsy histology as golden standard, is provided. Newer indices, such as 
exhaled nitric oxide (eNO), are described in more detail. Next, treatment guidelines of 
atopic asthma and possible future developments are discussed. It is concluded that 
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asthma is dealt with. Although a great part of patients and doctors beheve that most 
subjects with asthma will grow out of asthma in early adolescence, a considerable 
proportion of subjects in clinical remission of asthma will have a relapse later in life. It is 
suggested that ongoing ainvay inflammation and remodeling are the basis for this 
continuing risk on relapsing symptoms. The question is raised whether ongoing airway 
abnonnalities can indeed be demonstrated during clinical remission, and, if so, whether 
this ongoing inflammation should be treated with anti-inflammatory therapy. 
In Chapter 2, the aims of the studies are presented. This thesis aims to produce evidence 
of persistent airway inflammation and remodeling in young adults who seem to have 
outgrown their asthma. For this purpose, non-invasive as well as invasive methods are 
evaluated. Besides, symptom perception was measured to find an explanation for the 
discrepancy between the absence of symptoms and ongoing airway inflammation. 
Finally, we examined whether subjects with subclinical airway inflammation could 
benefit from anti-inflammatory treatment. 
In Chapter 3, non-invasive evidence of persistent airway inflammation during clinical 
remission of atopic asthma is demonstrated, as reflected by an elevated fraction of 
exhaled nitric oxide (FENO) levels and bronchial hyperresponsiveness to adenosine 
monophosphate (AMP) and methacholine (MCh). With respect to eNO, we found no 
overlap between values of21 subjects in clinical remission of atopic asthma and those of 
18 healthy controls. Values ofFENO in subjects in remission were similar to those of21 
subjects with current asthma. A significantly higher AMP- as well as MCh 
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responsiveness was present in the remission group as compared with the control group. 
Furthermore, AMP responsiveness showed a significant inverse relationship with FENO 
levels, probably suggesting that both indices are associated with active elements of 
airway inflammation, \vhereas responsiveness to MCh may also reflect airway 
remodeling. 
In Chapter 4, invasive "proof' of persistent airway inflammation and airway remodeling 
in the majority of subjects in clinical remission of atopic asthma complements the 
findings of chapter 3. By means of flexible bronchoscopy, bronchial biopsies were taken 
from 19 subjects with current atopic asthma, 18 subjects in clinical remission of atopic 
asthma, and 17 healthy controls. Immunohistochemical staining of biopsy specimens 
demonstrated an elevated density of eosinophils, T lymphocytes, mast cells, and IL-5 in 
the airways mucosa of subjects in remission compared to controls. Also, blood eosinophil 
cell counts were significantly elevated in subjects in clinical remission. Blood eosinophil 
cell counts, FENO levels, and bronchial response to AMP correlate significantly with the 
density of tissue eosinophils, indicating that these measurements could be used to 
monitor airway inflammation with minimal burden to the patient. 
MCh responsiveness did not show a relationship with the density of eosinophils in the 
airway mucosa. Since MCh is believed to act directly on smooth muscle cells in the 
airways, whereas AMP acts via activation of bronchial mast cells, it was concluded that 
AMP- and MCh responsiveness probably relate to different aspects of the inflammatory 
process. 
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Surprisingly, inducible nitric oxide synthase (iN OS) activity in the airway mucosa from 
healthy controls was higher than in subjects with asthma and subjects in remission. It 
could thus well be that iNOS-unrelated mechanisms, including augmented diffusion of 
NO through damaged epithelium, or iN OS independent NO generation under conditions 
of ainvay acidity may explain this finding. Furthermore, other isoforms of NOS could be 
responsible for elevated NO production. 
In conclusion, both ongoing airway inflammation and remodeling were demonstrated 
during clinical remission of atopic asthma, and can be monitored with non-invasive 
measurements. 
In Chapter 5, dyspnea perception was investigated in subjects in clinical remission of 
atopic asthma and subjects with current asthma. The hypothesis was that blunted 
symptom perception in subjects in clinical remission of asthma could explain the 
discrepancy between the lack of symptoms and persistent airway inflammation. Twenty 
subjects with bronchial hyperresponsiveness to MCh or AMP assigned themselves a 
perception score of dyspnea on a modified BORG scale at reaching a 20% fall in FEY 1 
(PS20) during MCh- or AMP challenge. Dyspnea perception was highly variable but did 
not differ significantly between both groups, nor between challenge tests. It was 
concluded that subjects in clinical remission are not different from currently asthmatic 
subjects with respect to their perception acute changes in FEY 1• Perception of symptoms 
in daily life might, however, be different from these results, since not only physical, but 
also emotional and social factors are believed to play a role in the subjective feeling of 
discomfort, and we can not exclude that daily life fluctuations in airflow limitation are 
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not well perceived by subjects in clinical remission of asthma. Therefore, the absence of 
symptoms in subjects with a past history of asthma does not mean that airway 
inflammation is gone. 
In Chapter 6, we assessed the effect of anti-inflammatory therapy in subjects in clinical 
remission of atopic asthma. It was hypothesized that if ainvay inflammation and/or 
remodeling are present during clinical remission despite a lack of symptoms, this could 
well respond to the use of inhaled steroids. A double-blind, randomized, placebo 
controlled trial with the salmeterollfluticasone propionate combination product (SFC 
50/250 !-lg bid via the DiskusrM inhaler) was conducted in 28 subjects in clinical 
remission with proven hyperresponsiveness to MCh as non-invasive indicator of 
ongoing disease. SFC treatment for three months improved PD20 MCh as well as PD20 
AMP, and nonnalized FENO in most subjects. SFC treatment also reduced mast cells 
in subepithelium, had a minimal effect on the thickness of the reticular basement 
membrane (RBM), but did not alter tissue eosinophils, blood eosinophils, and quality of 
life. The added value of the long acting fh agonist (salmeterol) could not be extracted 
from this study. It was suggested that airway hyperresponsiveness and FENO could 
represent fast responding elements of airway pathology, whereas tissue markers of 
inflammation and remodeling need more time than three months to respond. Based on 
the results of this study, the use of prolonged anti-inflammatory therapy during clinical 
remission of asthma is not justified. However, it encourages further investigation with 
long-term studies. ·whether inhaled steroids might prevent a relapse of asthma later in 
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life thus remains to be proven. Furthennore, major problems with therapy adherence in 
subjects without symptoms can be anticipated. 
In Chapter 7, an answer is sought to the question whether real asthma remission exists. 
The majority of subjects with childhood asthma seems to grow out of asthma in early 
adolescence. The appellation "clinical remission" is used in this context to define the 
absence of symptoms without therapy. Current classification guidelines do not mention 
this sizeable group of formerly asthmatic subjects who are at risk to develop symptoms 
again later in life, mostly before the age of 30. More specifically, epidemiological studies 
have shown that in about 30 to 80% of subjects in clinical remission of atopic asthma the 
absence of symptoms is only temporary. We postulate that this is due to persistent airway 
inflammation and remodeling. In about one fifth of the subjects in clinical remission in 
our study, significant airway inflammation and/or remodeling could not be demonstrated. 
Are these the subjects in true remission? If so, can we heighten this percentage with 
prolonged anti-inflammatory therapy? In Chapter 7 a review of the literature on asthma 
remission is given, thereby trying to find an answer to this questions. 
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Allergisch astma ontstaat meestal op jonge leeftijd, en wordt gekarakteriseerd door een 
chronisch ontstekingsproces in de luchtwegen. Veel patienten laten rond de puberteit een 
aanzienlijke vermindering van klachten zien, waarbij een groat dee! zelfs geheel 
klachtenvrij wordt en veelal geen medicatie meer hoeft te gebruiken. Dit noemen we 
"klinische remissie". In deze fase worden patienten uit de medische controle ontslagen, 
en wordt er veelal gesproken van "over astma been groeien". Uit een aantal studies is 
echter gebleken dat ongeveer de helft van deze ex-patienten op latere leeftijd, meestal al 
voor bet dertigste levensjaar, een recidiefkrijgt. Tijdens het "goede" interval zijn door 
sommige auteurs longfunctieafwijkingen vastgesteld, zoals verhoogde 
luchtwegprikkelbaarheid en luchtwegobstructie. Het is echter onduidelijk of deze 
afwijkingen verband houden met persisterende ontstekingsverschijnselen, dan wel met 
structurele veranderingen in de luchtwegen als uiting van "restschade" ten gevolge van 
astma op de kinderleeftijd. Tevens bestaat er onduidelijkheid over de relatie tussen de 
aard en uitgebreidheid van de ontstekingsverschijnselen en de prognose van astma. Het 
doel van ons onderzoek was nate gaan of bij person en met allergisch astma, die in 
klinische remissie zijn gekomen, aldan niet een ontstekingsproces in de luchtwegen 
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bestaat, en of, indien dit het geval is, dergelijke person en gebaat zijn bij het gebruik van 
ontstekingsremmende medicijnen. Tevens wordt er gezocht naar een verklaring voor de 
discrepantie tussen de afwezigheid van klachten en de aanwezigheid van het 
ontstekingsproces. 
In hoofdstuk 1 worden de epidemiologische aspecten en classificatie van allergisch astma 
besproken. Hoewel de aanwezigheid en uitgebreidheid van astmatische symptomen een 
belangrijk uitgangspunt iijken te vormen voor alle classificatiesystemen, wordt 
(chronische) \uchtwegontsteking tach als het kenmerkende element van allergisch- en 
niet allergisch astma gezien. 
Een overzicht van niet-invasieve en invasieve methoden om deze luchtwegontsteking te 
bestuderen, met luchtwegbiopten als gouden standaard, wordt in dit hoofdstuk gegeven. 
Nieuwere methoden, zoals het meten van de hoeveelheid stikstofoxide (NO) in 
uitgeademde Iucht, worden in detail beschreven. Het hoofdstuk wordt vervolgd met een 
uiteenzetting van de mogelijkheden van medicamenteuze therapie bij allergisch astma. 
Geconcludeerd wordt dat tot op heden inhalatiesterorden nog altijd de therapie van eerste 
keus vonnen. Als laatste wordt het gegeven van "over je astma heen groeien" nader 
uitgewerkt. Het feit dat een groat percentage van patienten, die menen over hun astma te 
zijn heen gegroeid, op latere leeftijd weer klachten krijgt, geeft a! aan dat de afwezigheid 
van symptomen blijkbaar niet de afwezigheid van ziekte impliceert. 
In hoofdstuk 2 worden de verschillende studies uiteengezet die als doe! hebben de 
aanwezigheid van luchtwegontsteking en/of remodeling aan te tonen bij personen die van 
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mening zijn over hun astma te zijn heen gegroeid. Voor dit doe! worden zowel niet 
invasieve als invasieve methoden geevalueerd. Daarnaast wordt er onderzocht of de 
verklaring voor de discrepantie tussen het gebrek aan klachten en de aanwezige 
luchtwegontsteking kan worden gezocht in veranderde syrnptoomperceptie. Als laatste 
wordt gekeken ofpersonen met niet-manifeste luchtwegontsteking voordeel kunnen 
hebben bij het gebruik van ontstekingsremrnende therapie. 
In hoofdstuk 3 werd bij patienten in klinische remissie van allergisch astma, bij patienten 
met actief astma en bij gezonden met niet-invasieve methoden gezocht naar persisterende 
luchtwegontsteking aangedragen. Hierbij werd gebruik gemaakt van NO in uitgeademde 
lucht en luchtweggevoeligheid voor adenosine monofosfaat (AMP) en metacholine 
(MCh). Met betrekking tot de uitgeademde hoeveelheid NO vonden wij geen overlap 
tussen meetwaarden van 21 personen in klinische remissie en die van 18 gezonde 
controlepersonen. Meetwaarden van personen in remissie bleken nauwelijks verschillend 
te zijn van die van 21 personen met symptomatisch astma. 
Tevens werd er een verhoogde luchtweggevoeligheid voor zowel AMP als MCh in de 
remissie groep gevonden, indien vergeleken met de controle groep. Daarnaast bestond er 
een duidelijke omgekeerde relatie tussen de reactie op AMP en hoogte van de 
uitgeademde NO hoeveelheid, hetgeen mogelijk impliceert dat beide variabelen 
gerelateerd zijn aan luchtwegontsteking, terwijl de reactie op MCh mede ofvooral 
beihvloed kan zijn door structurele afwijkingen. 
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In hoofdstuk 4 wordt invasief onderzoek naar bet bestaan van luchtwegontsteking en 
structurele afwijkingen bij de personen in klinische remissie van allergisch astma 
beschreven. Met behulp van flexibele bronchoscopie werden luchtwegmucosa biopten 
verkregen van 19 personen met symptomatisch astma, 18 personen in klinische remissie, 
en 17 gezonde controles. Irnmunohistochemische kleuring van bioptmateriaalliet een 
verhoogde dichtheid van eosinofielen, T lymfocyten, mestcellen, en IL-5 in bet 
luchtwegslijmvlies van personen in klinische remissie zien, wanneer werd vergeleken 
met gezonde controles. Tevens was de hoeveelheid eosinofielen in het bloed verhoogd. 
Er bleek een significant verband te zijn tussen eosinofielen aantal in bet bloed, 
uitgeademde hoeveelheid NO, en reactie op AMP enerzijds, en de mate van 
eosinofieleninfiltratie in het luchtwegslijmvlies anderzijds. Dit betekent dat dergelijke 
meetmethoden waarschijnlijk gebruikt kunnen worden om de aanwezigheid van 
luchtwegontsteking te controleren en te vervolgen, met mini male be lasting voor de 
patient. 
De reactie op MCh vertoonde echter geen relatie met de eosinofielen dichtheid in 
luchtwegslijmvlies. Daar MCh een direct effect uitoefent op de gladde spieren in de 
luchtwegen, terwijl AMP met name mestcel-degranulatie bewerkstelligt, kan worden 
geconcludeerd dat de reactie op AMP en MCh aan verschillende aspecten van bet 
ontstekingsproces gerelateerd zijn. Hierbij lijkt de reactie op MCh onatbankelijk van 
actieve luchtwegontsteking verhoogd te kunnen zijn. 
Een opvallende bevinding was tevens dat er een verhoogde activiteit van bet induceerbare 
stikstof oxide synthase (iN OS) in de luchtwegmucosa van gezonde controles aanwezig 
bleek te zijn, wanneer wordt vergeleken met de situatie in person en met symptomatisch 
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astma en person en in klinische remissie van astma. Dit was niet in overeenstemming met 
de aanname dat verhoogde iNOS expressie in de luchtwegmucosa de bron vormt van de 
verhoogde hoeveelheid NO in uitgeademde Iucht van personen met astma. Het is dus 
mogelijk dat niet aan iN OS gerelateerde mechanisrnen, waaronder toegenomen diffusie 
van NO door beschadigd epitheel ofveranderingen in de luchtwegzuurgraad, 
verantwoordelijk zijn voor dit onvenvachte resultaat. Daamaast kunnen andere vonnen 
van NOS een bijdrage leveren aan de verhoogde NO productie. 
Concluderend, zowel actieve luchtwegontsteking als structurele veranderingen zijn 
aantoonbaar bij personen in klinische remissie van atopisch astma, en kunnen worden 
aangetoond middels niet-invasieve meetmethoden. De recente bevindingen van diverse 
auteurs, waaronder verrninderde longfunctie en verhoogde luchtwegprikkelbaarheid 
tijdens het klinische remissie kunnen gerelateerd zijn aan zowel actieve ontsteking als 
structurele veranderingen in de luchtwegen. 
In hoofdstuk 5 werd de perceptie van kortademigbeid onderzocht bij personen in 
klinische remissie en bij personen met symptomatisch astma. De hypothese is dat 
verminderde symptoomperceptie bij personen in kliniscbe remissie de discrepantie tussen 
bet gebrek aan klachten en de persisterende luchtwegontsteking kan verklaren. Aan 20 
personen in klinische remissie, met verhoogde gevoeligheid voor MCh of AMP, werd 
gevraagd een kortademigheidscore toe te kennen bij bet bereiken van een 20 procent 
daling in FEY 1 tijdens MCh- of AMP provocatie. Kortademigheidperceptie bleek grate 
varia tie tussen personen te vertonen maar was niet duidelijk verschillend tussen personen 
in klinische remissie en person en met symptomatisch astma voor zowel MCh als AMP. 
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Geconcludeerd werd dat person en in klinische remissie niet verschillen van personen met 
symptomatisch astrna met betrekking tot de perceptie van een snelle opgelegde daling in 
FEY 1- De perceptie van astmatische symptomen in het dagelijks Ieven zou echter anders 
kunnen zijn, daar niet aileen lichamelijke, maar ook psychische en sociale factoren van 
invloed kunnen zijn op de beleving van symptomen. Er kan in ieder geval worden 
gesuggereerd dat de afwezigheid van symptomen bij personen met een voorgeschiedenis 
van astma niet hoeft te betekenen dat het ziekteproces in de luchtwegen is verdwenen. 
ln hoofdstuk 6 werd het effect van astrnabehandeling onderzocht bij personen in klinische 
remissie van astma. Hierbij werd uitgegaan van de hypothese dat, indien 
luchtwegontsteking en/of remodeling aanwezig blijven tijdens klinische remissie, 
subklinische ontstekingsverschijnselen kunnen venninderen door het gebruik van 
inhalatiesterorden. Een dubbelblinde, gerandomiseerde, placebo gecontroleerde studie 
werd daarom verricht met het salmeterollfluticasone propionate combinatie product (SFC 
50/250 !J.g 2dd via de Diskus™ inhaler) bij 28 personen in klinische remissie met 
bewezen hyperreactiviteit voor MCh als niet-invasiefkenmerk van luchtwegpathologie. 
SFC behandeling gedurende drie maanden venninderde in deze studie de 
hyperreactiviteit voor MCh en AMP, en nonnaliseerde de uitgeademde hoeveelheid NO 
bij de meeste person en in het onderzoek. 
Tevens werd er na drie maanden een duidelijke vennindering van mestcellen in het 
luchtwegslijmvlies, een geringe regressie van de dikte van de reticulaire 
basaalmembraan (RBM), maar geen significante vennindering van weefsel 
eosinofielen, bloed eosinofielen, en kwaliteit van leven gezien. De toegevoegde 
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waarde van een lang werkend 82- mimeticum kan uit de studieresultaten niet 
geextraheerd worden. Er werk gesuggereerd dat luchtwegreactiviteit en uitgeademde 
hoeveelheid NO mogelijk snel responderende elementen van luchtwegpathologie zijn, 
terwijl weefsel eosinofielen en andere invasieve kenmerken wellicht meer dan drie 
maanden nodig hebben om te reageren.Geconcludeerd werd dat de bevindingen van 
deze studie het (opnieuw) voorschrijven van ontstekingsremmende medicijnen aan 
personen in klinische remissie van astma niet rechtvaardigen. Wet moedigen deze 
resultaten aan tot lange-tennijn studies. De vraag of inhalatiesteroi'den een recidief van 
astma op latere leeftijd kunnen voorkomen blijft dus nog onbeantwoord. Daarnaast 
zullen problemen met de therapietrouw bij personen zonder klachten dergelijk lange-
tennijn onderzoek niet vereenvoudigen. 
In hoofdstuk 7 wordt benadrukt dat een meerderheid van de jeugdige patienten met astma 
in de vroege pubertijd over het astma been lijkt te groeien. De term "klinische remissie" 
wordt in deze context gebruikt als aanduiding voor de afwezigheid van symptom en 
zonder het gebruik van inhalatie medicatie gedurende tenminste 1 jaar. 
Binnen de huidige classificatiesystemen is deze omvangrijke groep van volledig 
klachtenvrije astmapatienten in het geheel niet terug te vinden, ondanks het feit dat dezen 
vaak op latere leeftijd een recidiefvan astmatische klachten krijgen, over het algemeen 
zelfs a] voor het dertigste levensjaar. Epidemiologische studies hebben aangetoond dat bij 
30 tot 80% van personen in klinische remissie de afutezigheid van syrnptomen slechts 
tijdelijk is. Er wordt naar voren gebracht dat persisterende luchtwegontsteking dit 
aanzienlijke risico op een recidief zou kunnen veroorzaken. In ongeveer 20 procent van 
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de person en in klinische remissie in ons onderzoek konden geen luchtwegontsteking 
en/of structurele afwijkingen meer worden aangetoond. Zijn dit dan de person en in echte 
remissie? En zo ja, kunnen we dit I age percentage dan verhogen middels langdurige 
ontstekingsremrnende behandeling? In hoofdstuk 7 wordt een overzicht van de 
beschikbare literatuur over astma remissie gegeven, waarbij getracht wordt een antwoord 
op deze vragen te geven. 
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AMP 
ATS 
BHR 
CRF 
eNO 
FENO 
FE VI 
HASM 
IL-5 
iN OS 
MBP 
MCh 
PEFR 
RAST 
RBM 
adenosine-5' -monophosphate 
American Thoracic Society 
bronchial hyperresponsiveness 
clinical research file 
exhaled nitric oxide 
fraction of exhaled nitric oxide 
forced expiratory volume s-1 
human airway smooth muscle 
interleukin-5 
inducible nitric oxide synthase 
major basic protein 
methacholine 
provocative dose resulting in 20 percent decrease in FEY 1 
peak expiratory flow rate 
perception score at reaching a 20 percent decrease in FEV1 
radioallergoimmunosorbent test 
reticular basement membrane 
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SFC salmeterollfluticasone propionate combination 
Th2 type 2 T-helper 
TLC total lung capacity 
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Collega G. T. Verhoeven zei ooit: "bet is eenvoudiger om meerdere marathons uit te 
lopen dan eenmaal te promoveren". Daar deze uitspraak na maar liefst vijfmarathons tot 
stand is gekomen, moeten we wei aannemen dat het voltooien van een proefschrift een 
uitputtende bezigheid is, die met een wazige blik op de finish en een wisselend gevoel 
van verzuring gepaard kan gaan. In het zicht van- en vooral na het bereiken van de finish 
slinkt het pijngevoel echter snel, en telt uitsluitend nog bet resultaat. Ook het volbrengen 
van slechts twee marathons heeft de schrijver van dit proefschrift de overtuiging gegeven 
dat ook het "finishgevoel" bij het promotieonderzoek een gevoel van voldoening moet 
zijn. De blessures zijn echter van behoorlijke omvang en geven soms een nieuwe 
dimensie aan het begrip "beroepsgerelateerde aandoeningen". Naast de alom bekende 
muisarm was er bij mij sprake van een "microfilm-nystagmus" (na het beoordelen van 
ongeveer 2000 patientendossiers op voorbij rollende microfilm) en "image analysis 
hallucinaties" (het herkennen van een basaalmembraan in de trapleuning). Gelukkig 
waren dergelijke ongemakken van tijdelijke aard en hebben zij er niet toe geleid dat voor 
de finish moest worden uitgestapt. Dit proefschrift zou echter niet tot stand zijn gekomen 
zonder de hulp van velen die nu snel doorlezen of ze daadwerkelijk met name worden 
genoemd. In zijn algemeenheid verdienen het laboratorium longziekten in de hoogbouw, 
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de afdeling longfunctie en de mensen van het archiefvan het Sophia 
Kinderziekenhuis, de verpleegkundigen in de bronchoscopiekamer, Glaxo SmithKline 
B.V., en natuurlijk aile proefpersonen mijn speciale dank. Aan enkele personen wil ik 
echter enige persoonlijke woorden wijden. 
Prof. Dr H.C. Hoogsteden, beste Henk, ik wil je bedanken voor de mogelijkheid die je me 
hebt geboden om dit onderzoek te verrichten, ook al sloeg de twijfel enigszins toe toen je 
venneldde dat ik gerust elk weekend in het medisch archie£ door "mocht" werken, nadat 
ik a! op zondag was komen opdraven voor het sollicitatiegesprek. Daarnaast heb je me 
echter vee! vrijheid gegeven bij de invulling van het onderzoek, hetgeen ik zeer waardeer. 
Prof. Dr J.C. de Jongste, beste Johan, je wonderbaarlijk snelle en secure correctie van 
mijn wetenschappelijke probeersels hebben mij telkens aangenaam verrast. Je gewoonte 
omje commentaar te starten met: "dit wordt weer een schitterend artikel" (om 
vervolgens bijna elke zin met de rode stift te bestormen) heb ik als zeer prettig ervaren. 
Ook je uitgebreide literatuurkennis en neus voor belangrijke ontwikkelingen zijn van 
grote waarde geweest. 
Dr S.E. Overbeek, beste Shelley, onze onderzoeksrelatie heeft een intens karakter 
gekend. Je historische uitspraken tijdens de uitvoering van een bronchoscopie ("ik zie 
niks!" of"wat is dat bloederig!") zal ik (en zullen de proefpersonen) niet snel vergeten. 
We zullen bet wel nooit eens worden wie van ons tweeen bet opstapbankje bij de 
bronchoscopie harder nodig heeft. Je enorme inzet en belangstelling voor bet onderzoek, 
maar ook voor bet thuisfront, zijn bewonderenswaardig. Bedankt voor al je hulp! 
Dr J-B Prins, beste Jan-Bas, op bet moment dat ik dit schrijfbenje al niet meer 
werkzaam in de Erasmus Universiteit. Aanjou verliest het laboratorium een persoon met 
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vele kwaliteiten. Je bijzonder kritische noot en schijnbare onbekendheid met het woordje 
"goed" hebben onze samenwerking echter niet altijd tot een gemakkelijke gemaakt. Na 
een bezoek aanje kamer op de 22e vroeg ik me vaak af: "is er nog leven na(ast) het 
promotieonderzoek?". Gelukkig heb je buiten bet werk Iaten zien ook over een andere en 
gezellige persoonlijkheid te beschikken. Daamaast heb je op velerlei wijze, waaronder je 
vakkundige begeleiding bij bet maken van voordrachten, jc waarde voor dit onderzoek 
bewezen, waarvoor ikje veel dank verschuldigd ben. 
Van de longafdeling verdient Joachim Aerts bet nag om nader aangehaald te worden. 
Zijn bereidwilligheid om de laatste patienten voor bet onderzoek te zien zal ik niet 
vergeten, oak al heeft het me enige tijd en hoofdbrekens gekost de juiste gegevens bij de 
juiste patient te plaatsen. Joachim bedankt! 
Van bet laboratorium longziekten in de hoogbouw verdienen twee mensen een extra 
woord van dank: Joost Hegmans, jou wil ik bedanken voor je constante bereidwilligheid 
te helpen met laboratoriumzaken waar ik te weinig verstand van heb. De te nemen 
stappen bij het opstarten van de image analysis computer zullen wei nooit voor tangere 
tijd in mijn geheugen gegrift blijven staan. Karolina Leman, hoewel we bet niet altijd 
eens waren over de manier waarop een lijn tangs een basaalmembraan getrokken meet 
worden, is bet vele snij- en kleurwerk datje samen met Sophia hebt verricht van 
onschatbare waarde geweest. 
Van de afdeling longfunctie in het Sophia Kinderziekenhuis wil ik Astrid, Simone, 
Marieke, Aafke en Edith bedanken voor hun tomeloze inzet bij de longfunctiemetingen 
en hun oneindige geduld wanneer ik weer eens een meting liefst direct of anderszins 
tussendoor wilde. 
175 
Chapter 12 Dankwoord 
Het Nederlands Astma Fonds dank ik voor de financiele ondersteuning van het 
"hoofdonderzoek". 
Van Glaxo SmithKline wil ik Pauline Bloemen en Martijn Akveld bedanken voor de 
zorgvuldige en gezellige begeleiding van de interventiestudie. De kalme reactie van 
Pauline op het feit dat ik een geleende laptop heb late crashen verdient aile !of Oat ze mij 
vervolgens uit protest een andere computer in bruikleen heeft gegeven die nauwelijks 
meer tot enigerlei bewerking te motiveren was, is volkomen begrijpelijk. 
Bij de eenzame uren in het archie£ in het Sophia Kinderziekenhuis heeft Maarten mij 
altijd met woord en daad terzijde gestaan. 
Paul Mulder dank ik voor bet feit dat hij mij heeft bijgestaan in de soms moeilijk te 
doorgronden brij van de statistiek. De uiting "ieder zijn vak" heb ik bier altijd voor ogen 
gehouden. 
Van het Sint Fransiscus Gasthuis wil ik niet nalaten Arie Rietveld te noernen die mijn 
interesse voor de intensive care geneeskunde tot grate hoogten heeft weten te doen 
stijgen. Arie, bet steeds weer kopieren van "Up to Date" heeft me weliswaar enige flessen 
wijn gekost, maar weegt ruimschoots op tegen de vele plezierige en leerzame momenten 
die ik op de IC hebben gehad. Ook dank ikje voor je min ofmeer subtiele pogingen om 
mijn ecbtgenote te overtuigen van bet nut van een eigen snowboard. Daamaast wil ik van 
betzelfde gasthuis Arjan Rudolphus bedanken voor zijn zachte drang om mij met links te 
Iaten scopieren, en Youke Tan alsnog mijn verontschuldigingen aanbieden voor bet feit 
dat ik een (oude) scoop ondanks bijtring door een patiente aan flarden heb Iaten bijten. 
Tevens is uiteraard een woord van dank voor de vele proefpersonen die aan het 
onderzoek hebben meegewerkt op zijn plaats. AI varieerde de reactie na een 
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bronchoscopie nog van "piece of cake" tot "never nooit meer", na de provocatietcsten 
waren sommigen zelfs niet meer in staat om hun reactie te geven ( omdat ik bet nodig 
vond de FEY 1 tot onder 40% van de beginwaarde te I a ten dalen). De bereidwilligheid om 
bet gehele onderzoek te doorlopen was bij vrijwel a lie deelnemers daarom 
indrukwekkend. Het feit dat een aantal van hen de in het vooruitzicht gestelde riante 
vergoeding al ruimschoots hadden uitgegeven doet bier niets aan af. 
Patrick Jongmans, bedankt voor je on twerp van de oms lag van het boekje en je hulp als 
de computer weer eens niet deed wat ik wild e. Het tekentje dat je best paranimfwilde 
zijn ondanks het feit datje dat erg dubieus vond klinken. 
Het recht om als last but zeker not least in dit dankwoord te staan komt mijns inziens 
zonder twijfel toe aan degene die tevergeefs bleef vragen of ze kon helpen om bet 
onderzoek te bespoedigen. Lieve Angeli que, je hebt vaak Largo aileen moeten uitlaten 
omdat ik weer eens achter de computer wilde duiken, maar nu is dat "stomme onderzoek" 
toch eindelijk af. Ik beloofje dat we weer vaker samen leuke dingen gaan doen. Jij deed 
me immers telkens weer realiseren dater nog leven is na(ast) bet promotieonderzoek. 
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Leon Michie! van den Toorn werd geboren op 16 februari 1966 te Amsterdam. Het 
diploma 0-VWO behaalde hij in 1984 aan het Bonhoeffer College te Castricum. In 1989 
voltooide hij de studie medische biologic aan de Vrije Universiteit te Amsterdam. Tijdens 
deze studie liep hij onderzoeksstages op de afdeling fysiologie (Dr G.C. van den Bos) en 
interne geneeskunde (Prof Dr. R.O.B. Gans). In 1987 was hij tevens begonnen met de 
studie geneeskunde aan dezelfde universiteit, hetgeen resulteerde in een met succes 
afgelegd arts exam en in 1994. Vervolgens was hij gedurende twee jaar werkzaam als 
AGNIO interne geneeskunde, longziekten en cardiologic in het Spaame Ziekenhuis te 
Heemstede. Alhier werd zijn belangstelling voor de longziekten gewekt, hetgeen een 
AGNIO-schap longziekten in bet Academisch Ziekenhuis te Rotterdam ten gevolge had. 
Op 1 april 1997 werd tevens een start gemaakt met voorliggend promotieonderzoek 
(promotoren Prof. Dr. H. C. Hoogsteden en Prof. Dr. J.C. de Jongste) op de afdelingen 
longziekten (Erasmus MC Rotterdam) en kindergeneeskunde/subafdeling 
kinder!ongziekten (Erasmus MC locatie Sophia). Vanaf 1 juli 2000 tot 1 maart 2002 heeft 
hij als AGIO longziekten zijn vooropleiding interne geneeskunde in het St. Fransiscus 
Gasthuis te Rotterdam doorlopen (opleiders Dr. Tjen en Prof. Dr. H. C. Hoogsteden). 
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Sinds 1 maart 2002 is hij voor de vervolgopleiding longziekten weer werkzaam in bet 
Erasmus MC. 
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